| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Department of Transplant Surgery, Medical College of Wisconsin,
Froedtert Memorial Hospital (Milwaukee).
Correspondence to Dr Galen M. Pieper, Department of Transplant Surgery, Medical College of Wisconsin, Froedtert Memorial Hospital, 9200 W Wisconsin Ave, Milwaukee, WI 53226. E-mail gmpieper{at}pot.its.mcw.edu
Endothelial dysfunction is characterized by defective
endothelium-dependent relaxation, and some reviews
regarding endothelial dysfunction in diabetes have been
published.5 6 7 8 These reviews have focused on
factors that might contribute to defective relaxation, some of which
will not be addressed in detail in this review. The purpose of the
present review is to summarize evidence that specifically supports
either decreased NO production by diabetic vascular
endothelium and/or impaired NO-mediated
endothelium-dependent relaxation. Second, this review
provides reasonable alternatives to explain some of the controversies
in this research area. Third, since there is growing evidence that
arginine appears to have some benefits for diabetes-associated
abnormalities, this review summarizes the current state of knowledge of
effects of acute and chronic administration of L-arginine
on diabetes-induced endothelial dysfunction and
discusses potential NO-dependent and -independent mechanisms whereby
therapeutic intervention with L-arginine might benefit the
diabetic endothelium.
Almost without exception, studies that have shown impaired
endothelium-dependent relaxation have found normal
relaxation to nitrovasodilators. These agents relax vascular smooth
muscle by activating guanylate cyclase but, unlike NO, do
not require the presence of the endothelium. Thus, the
intrinsic property to activate vascular smooth muscle
guanylate cyclase appears not to be altered by experimental
diabetes.
Studies in experimental models of NIDDM are few and controversial. In
the obese Zucker rat, no alteration in
endothelium-dependent relaxation has been observed in
intestinal microvessels,38 whereas increased
reactivity has been observed in aorta.39 40 In
contrast, decreased endothelium-dependent relaxation to
acetylcholine but not to A23187 was seen in aorta in male (but not
female) JCR:LA-corpulent rats.41 Little is known
regarding the nature of endothelial dysfunction in
these models.
Conclusion. Collectively, these studies suggest that
endothelial dysfunction (1) is not unique to chemically
induced experimental models of IDDM, (2) is found in both conduit and
resistance arteries, and (3) cannot be explained by an intrinsic change
in reactivity to NO or guanylate cyclase reactivity.
Studies conducted in experimental models of NIDDM are few and provide
no clear consensus regarding this issue.
Human Diabetes Mellitus
Several investigators have observed normal relaxation to
nitrovasodilators in diabetic
patients.42 43 44 45 46 47 51 52 53 55 56 57 58 59 60 In contrast, other
investigators have noted attenuated responses to nitrovasodilators in
IDDM diabetic patients54 61 62 63 and in NIDDM
diabetic patients.48 49 50 64
Conclusion. The majority of studies have demonstrated
impaired endothelium-dependent relaxation. In contrast,
there is not sufficient consensus on whether vascular smooth muscle
reactivity to NO is compromised in human diabetes mellitus.
There are several concerns regarding critical evaluation of the data
obtained in diabetic patients. Whereas some investigators have
carefully eliminated patients taking medications (eg, vasoactive and
cardiovascular drugs) and have limited intake of
caffeine or alcohol before evaluation, other investigators have either
not provided information regarding patient selection or have ignored
these potential influences. Some studies have included patients with
histories of smoking (an independent risk factor for
endothelial dysfunction) or have only limited smoking
just before the study.
Most studies have used a mixed-gender patient population. Thus, the
influence of gender-related differences has not been isolated. Indeed,
it is widely known that diabetes-induced complications are enhanced in
the female population. A recent study has revealed diminished reactive
hyperemia (an endothelium-related phenomenon)
in young female IDDM patients compared with age-matched male
subjects.67 Furthermore, inclusion of postpuberty
female patients using oral contraceptive agents has been acknowledged
in some studies,61 62 but the significance of
inclusion of this subpopulation has not been addressed. In studies
using male subjects only, endothelial function was
either impaired46 47 49 50 or
unchanged.54 55 57
In studies of vascular reactivity using NIDDM patients, it was
acknowledged that many subjects were receiving hypoglycemic drugs or
insulin at the time of
evaluation.47 48 49 51 52 64 68 Oral hypoglycemic
agents such as glibenclamide can impair dilation mediated by
NO-mediated KATP channel
activation.69 Thus, the effects of this
medication on NO-mediated relaxation have not been uniformly excluded.
One study showed no difference in endothelium-dependent
relaxation between patients taking oral hypoglycemic agents and those
controlling the disease by diet alone.48 In one
study in which hypoglycemic medication was removed for a finite period
before evaluation, there was diminished reactivity to acetylcholine but
not to nitroprusside.53
Endothelial function in patients has been determined in
vivo using either strain-gauge plethysmography or Doppler
techniques, predominately in brachial/forearm protocols. A few have
evaluated dilation in the femoral artery53 63 64
or coronary arteries.43 While there is
important value in examining reactivity in vivo under ambient
conditions, there are several significant complicating factors that
make the in vivo delineation of mechanisms difficult. For example, one
investigator found that endothelial dysfunction
correlated with serum triglyceride and lower HDL
cholesterol levels.50 Furthermore,
ambient glycated proteins may diminish
endothelium-dependent relaxation studied in
vitro,70 71 although a recent in vitro study in
canine conduit and resistance artery preparations could not confirm
this effect.72
Conclusion. Patient selection and screening have the
potential to explain differences in findings obtained in clinical
studies. The potential influence of gender, presence of
microalbuminuria, and use of medications, including oral
contraceptives and hypoglycemic agents, need to be rigorously evaluated
in clinical studies. Also, the influence of ambient glucose
concentration, glycated proteins, and lipids on
endothelial function needs to be considered in clinical
evaluations.
An immediate acute effect of elevated glucose concentration is a marked
increase in basal [Ca2+]i
and NO production in isolated human endothelial
cells.84
[Ca2+]i also increases
rapidly (within minutes) in the presence of elevated glucose
concentration in isolated bovine aortic endothelial
cells (G.M.P., unpublished observation, 1997). This effect may persist
for several hours after exposure to elevated glucose
concentration.85 In contrast, after 24 hours of
exposure of bovine aortic endothelial cells to elevated
glucose and subsequent analysis under normal glucose
conditions, basal [Ca2+]i
and NO production returned to normal, whereas
bradykinin-stimulated
[Ca2+]i and NO
production was reduced.86 Similarly,
impaired agonist-stimulated
[Ca2+]i and NO
production have been observed after exposure of rat or
porcine endothelial cells to elevated glucose
concentration.87 88
To circumvent this potential limitation, one study using the
euglycemic insulin clamp protocol46
revealed that endothelial function was diminished.
Also, analysis in vitro of human gluteal resistance arteries
under normoglycemic conditions also revealed diminished
endothelium-dependent
relaxation.45 The latter study suggested an
intrinsic defect in endothelium-dependent relaxation in
IDDM that is independent of direct effects of concurrent ambient
glucose concentrations in vivo. In contrast, another study showed that
relaxation to carbachol was unchanged in IDDM patients under
euglycemic conditions produced by insulin
infusions.56 Interestingly, a defect in NO
synthesis was still suggested in patients with
microalbuminuria based on the lack of response to
NG-monomethyl-L-arginine
(L-NMMA).
Conclusion. The confounding effects of ambient glucose
concentration on endothelial function in studies
performed in patients and in experimental diabetes in vivo should be
taken into account when glucose concentration is not normalized.
Unfortunately, controlling for this contingency may be difficult,
particularly in clinical studies. Clearly, there are important direct
stimulatory and inhibitory effects of elevated glucose
concentration on vascular reactivity that may be manifested at
different times subsequent to rises in glucose concentration.
Interestingly, there are paradoxical reports of normal
endothelium-dependent relaxation in aorta after >12
weeks of diabetes93 94 95 and after 15 to 17 weeks
of diabetes in perfused mesenteric
preparations.96 The reasons for these disparate
observations compared with other findings are unclear. Potential
explanations might include the use of helical
strips,93 diabetes-induced hypersensitivity to
phenylephrine and evaluation only in
indomethacin-treated
preparations,94 use of a low dose of
streptozotocin,94 or the potential influence of
masking by crossover effects due to multiple drug
challenges.95
There is clinical and experimental evidence showing augmented blood
flow at early stages of diabetes.97 It is not at
all clear whether this increased blood flow reflects increased
NO-specific endothelium-dependent dilation. One
possibility that needs to be examined is whether the diabetes-induced
decreases in 2,3-diphosphoglyceric acid levels in red blood
cells,98 which regulate oxygen release from
hemoglobin, lead to a "hypoxic-like"
environment.99 Decreases in tissue ATP
concentration could result in increased blood flow due to
hypoxic-induced dilation in compensation for reduced oxygen delivery to
tissue. Indeed, myocardial ATP concentration is reduced in diabetes but
is rapidly replenished within minutes of perfusion in vitro with
oxygenated blood-free salt
solutions.100 Furthermore, in situ
analysis using microelectrodes reveals diminished oxygen
tension in aorta of alloxan-diabetic rabbits.101
Thus, increase in tissue blood flow at the early stages of diabetes may
be due to hypoxic vasodilation. Alternatively, increased blood flow may
be a direct response to acute or short-term hyperglycemia, since
coronary blood flow is increased with glucose infusions in
isolated hearts in the presence of
indomethacin.75
At least one study has noted augmented
endothelium-dependent relaxation in
indomethacin-treated rat renal arteries at an early
stage of diabetes.102 Because
endothelium-dependent relaxation is reduced in renal
arteries of diabetic rats of longer disease
duration,103 this observation raises the
possibility that diabetes induces biphasic effects on
endothelium-dependent relaxation. Thus, an early
increase in blood flow may be followed by a transition state to
impaired relaxation. In support of this hypothesis, one study noted an
increase in endothelium-dependent relaxation of
mesenteric arteries to both acetylcholine and bradykinin at 6 weeks of
diabetes that reverts back to normal after 12
weeks.104 This enhanced relaxation could not be
accounted for by intrinsic changes in smooth muscle reactivity because
responses to sodium nitroprusside were normal.
It remains to be resolved in temporal studies using various
preparations whether the enhanced endothelium-dependent
relaxation at early stages might be due to diabetes-induced increases
in synthesis of vasodilator prostaglandins, EDHF, or NO, or
a combination of any of these endothelium-derived
factors. In this regard, studies conducted in
mesenteric104 and renal102
arteries in the presence of indomethacin suggest that
vasoactive prostanoids do not contribute to enhanced
endothelium-dependent relaxation, leaving EDHF and NO
as candidate factors.
Conclusion. Time of evaluation after onset of disease
may be critical to demonstrating endothelial
dysfunction. Indeed, evidence exists for enhanced
endothelial function at early stages followed by
dysfunction at later stages. Whether these opposing actions are
causally linked is not yet known. Further studies are warranted to
understand this temporal dichotomy.
Simultaneous enhancement and release of vasoconstrictor
prostaglandins may explain some instances of impaired
endothelium-dependent relaxation. Indeed, in aorta,
pial artery, and mesenteric artery, relaxation is either
normal94 or is normalized in the presence of
indomethacin or thromboxane receptor
antagonists.13 21 103 106 In
contrast, endothelial function was normal in
coronary arteries of alloxan-diabetic dogs, but dysfunction was
unmasked in the presence of inhibitors of
cyclooxygenase,11 107
suggesting enhanced compensatory increases in vasodilator prostanoid
release. Furthermore, increases in production of the
vasodilator prostacyclin have been reported in perfused mesenteric beds
of 3-week diabetic rats.108 While not directly
examined, this might provide an alternative explanation for one of the
early reports showing augmented relaxation to the agonist histamine in
mesenteric arteries of diabetic rats109 or the
observation of normal relaxation seen in perfused mesenteric beds of
long-term diabetic rats.94 In contrast, this may
not be adequate to explain the increased
endothelium-dependent relaxation seen in perfused
kidney at early stages of disease, since this increase was seen in
indomethacin-treated
preparations.102
One investigator has shown that thromboxane receptor
antagonism does not alter relaxation in basilar
artery110 but restores relaxation of pial
arteries taken from the streptozotocin-diabetic rat
model.21 These observations suggest important
regional differences, although one cannot exclude the possible
contribution of the superimposition of the variable in the duration
of disease, which was 4 to 5 months in the basilar artery study versus
2.5 to 3.5 months for the pial artery study. In another model of
alloxan-diabetic dogs in which duration of disease was held constant,
inclusion of indomethacin or ibuprofen unmasked a
defect of endothelium-dependent relaxation in
coronary artery11 but not renal
artery.111 Collectively, these studies suggest
important regional differences in the mechanism of
endothelial dysfunction.
Many studies using either rat conduit
arteries9 14 16 17 18 112 113 114 or rat resistance
arteries25 26 91 103 115 116 117 have indicated no
improvement in endothelial function after evaluation
under conditions of cyclooxygenase blockade or
thromboxane receptor antagonism. Similar interventions have
failed to modify defective relaxation in aorta of the genetic diabetic
BB rat33 and in coronary arteries of
alloxan-diabetic dogs.20
The effect of prostanoids on endothelial function in
human diabetes has not been routinely evaluated. Prior treatment with
indomethacin in vitro normalized impaired
endothelium-dependent relaxation in cutaneous arteries
of gestational diabetes.118 In contrast, in one
human study in which all patients received aspirin before
evaluation,44 the authors concluded that
exogenous prostanoid synthesis cannot account for the
endothelial dysfunction in IDDM.
Conclusion. There exist some potentially important
regional differences in the role of prostanoids in contributing to
altered endothelium-dependent dilation in diabetes
mellitus, although this cannot be easily predicted among various
conduit versus resistance vessels. Nevertheless, there is clear and
ample evidence to suggest that alterations in prostanoid
production may not always account for and/or may not be
obligatory for impaired endothelial function in
diabetes.
EDHF appears to activate K+ channels,
especially calcium-activated K+
channels.119 The contribution of
KATP channels to relaxation in diabetes is
uncertain and should also be considered. A few studies have noted
diminished responses to KATP channel openers in
diabetic rat aorta15 121 122 and basilar
artery.123 One study in the aorta of WBN/Kob rat
showed no alteration in relaxation to the KATP
channel agonist cromakalim.124 In contrast,
others have observed a paradoxically enhanced response in dog
coronaries to aprikalim, albeit in short-term
diabetes.125 In normal arteries, it is generally
believed that the component of EDHF versus NO that contributes to total
relaxation increases with decreasing vessel size. The observation that
diabetes-induced endothelial dysfunction can occur in
both conduit and resistance arteries despite
cyclooxygenase blockade suggests that this
dysfunction could be explained by defects in EDHF or by deficits in NO
synthesis unrelated to or in addition to changes in EDHF or
prostanoids.
Two studies in rat aorta reveal that endothelial
dysfunction persists despite pretreatment with TEA (to inhibit
calcium-activated K+ channels),
suggesting that defects in EDHF may not be
operative.126 127 Alternatively, a recent study
in perfused kidney indicates that endothelium-dependent
relaxation in control kidney arises from both NO and EDHF, whereas
relaxation in diabetic kidney arises from NO, EDHF, and
prostanoids.128
Few studies have examined perturbations in membrane polarization in
diabetic vascular tissue. Membrane
hyperpolarization is known to occur in gastric
gland of 2- to 3-day diabetic rabbits129 and in
endothelial cells from human subjects with gestational
diabetes.130 One study showed normal resting
membrane potential but diminished hyperpolarization
in the response of diabetic mesenteric artery to
acetylcholine131 despite unaltered
hyperpolarization in response to the
K+ channel agonist pinacidil. This report
conducted in the presence of NOS and cyclooxygenase
inhibitors suggested diminished
endothelium-dependent, TEA-sensitive
hyperpolarization and relaxation.
Conclusion. Endothelial dysfunction in
some cases of diabetes and in certain blood vessel types may arise from
deficits in EDHF, but it is also clear that endothelial
dysfunction can also occur despite blockade of EDHF and prostanoid
synthesis and action, suggesting a role for deficits of
endothelium-derived NO. It is possible that previous
studies may need to be carefully reevaluated, since alternative
compensatory pathways including cytochrome P450–derived EDHF may be
activated or inactivated, which could mask impaired
endothelium-dependent relaxation or compensate for
defective NO synthesis. It should be emphasized that parallel
compensatory pathways may be important at certain stages but perhaps
not at all stages of the disease.
Currently, there have been no studies that have directly determined NO
synthesis or release from diabetic endothelium. Only
one laboratory has examined intraluminal release of NO activity from
perfused diabetic rat aorta donor segments using the bioassay
technique.133 Accordingly, luminally released
basal NO activity in perfused diabetic rat aorta was normal, but
addition of SOD caused a larger incremental increase in relaxation of
the bioassay detector when the diabetic donor segment was used. This
suggested the increased release of superoxide anion radicals from
diabetic rat endothelium. In contrast,
acetylcholine-stimulated endothelium-derived relaxing
factor/NO bioactivity from perfused diabetic rat aorta was diminished
but also normalized by perfusion with SOD.114
Conclusion. Several studies support the concept that
IDDM decreases NO bioactivity. This may be due in part to enhanced
destruction of NO by increased superoxide synthesis.
Indirect Evidence Using Guanylate Cyclase
Inhibitors
Two studies noted enhanced contraction to methylene blue in control
versus diabetic rat aorta ring preparations, suggesting diminished
basal NO in diabetic arteries.16 133 The use of
methylene blue alone is inadequate because of the known effects of
methylene blue to stimulate superoxide anion radical or inhibit
NOS.146 147 One study using a new highly
selective inhibitor of guanylate cyclase, ODQ,
revealed that ODQ completely inhibits acetylcholine-induced relaxation
in control rat aorta and inhibits relaxation in diabetic rat aorta by
80%.148 This suggests that almost all of the
relaxation in both groups is mediated by cGMP activation, implicating
NO as the EDRF. Also, the small ODQ-resistant component of
relaxation in diabetic rat aorta leaves open the possibility of some
other unknown factor that appears unrelated to vasodilator prostanoids,
H2O2, or a TEA-sensitive
EDHF.
Conclusion. Overall, these studies suggest diminished
basal NO production in diabetes.
Evidence Using NO Trapping Agents
In contrast, despite nearly complete inhibition of
acetylcholine-mediated relaxation by both control and diabetic rat
aorta by NOS inhibitors, use of a nitronyl nitroxide
revealed an NO scavenger–resistant component of
agonist-stimulated relaxation that is greater in diabetic than control
arteries.148 This resistant component of
endothelium-dependent relaxation was sensitive to NOS
inhibitor but was insensitive to
indomethacin, TEA, or catalase, suggesting that this
additional EDRF is likely not EDHF, prostanoids, or
H2O2. A significant portion
of this resistant component was eliminated using ODQ,
suggesting that this EDRF is an activator of
guanylate cyclase. Current research continues to attempt to
identify whether diabetic arteries produce an additional vasoactive
product that is derived from the NOS reaction but that may not
necessarily be a free NO radical.
Measurement of NO by cGMP Generation
There is no apparent intrinsic change in either guanylate
cyclase or phosphodiesterase activity of vascular smooth muscle to
account for defective cGMP production in diabetic blood
vessels. The evidence suggests decreased basal and agonist-stimulated
NO bioactivity in experimental diabetes mellitus.
Measurement of NO or NO By-products
Some studies have reported increases in both urine and plasma
nitrate+nitrite concentration in diabetic
animals.157 158 159 161 In contrast, levels of
plasma nitrate163 and of
cGMP164 were normal in diabetic patients.
Although nitrate levels were normal,163 exhaled
NO level was decreased by 30% but did not reach statistical
significance because of the small sample size. Infusion of L-NMMA
caused a greater decrease in exhaled NO in healthy versus diabetic
patients, although nitrate levels did not change, suggesting decreased
NO synthesis. Nevertheless, changes in plasma NO do not provide
concrete information regarding the location and source of NO
production.
Conclusion. Measurement of nitrate/nitrite in plasma and
urine in experimental diabetes supports increased NO production.
Because the source of this increased nitrate and nitrite is not easily
ascertained, conclusions regarding endothelial cell NO
production based on these measures alone are hazardous and must
be taken as confirmation of other derived parameters.
Measurement of NOS Protein, mRNA, or Activity
Consistent with these reports are increases in mRNA and/or
protein for cNOS after culture with elevated glucose concentrations in
bovine aortic endothelial cells for 24 hours (G.M.P.,
unpublished observations, 1997) and in human aortic
endothelial cells after 5
days.170 In contrast, longer-term culture under
high glucose conditions of human umbilical vein
endothelial cells revealed no alteration in either mRNA
or protein for cNOS.171 This suggests either
heterogeneity in the response of different
endothelial cells or glucose concentration–dependent
and/or exposure time–dependent differences.
In the diabetic heart study, the finding that normal or enhanced NOS
activity occurs under acellular conditions despite concomitant
decreases in endothelium-dependent relaxation indicates
no intrinsic defect in NOS activity. This is consistent with
elevations in mRNA for endothelial cell–derived NOS despite decreased
NO production in endothelial cells cultured
with elevated glucose for 24 hours.86
In isolated endothelial cells from diabetic BB
rat,172 nitrate/nitrite production in
culture was diminished, as well as citrulline production from
arginine, and occurred without changes in arginine uptake. The latter
suggests no defect in the y+ transporter function
in these cells. In contrast, alloxan diabetes enhanced cGMP
production and increased both Vmax and
Km for arginine in gastric
glands.129 The significance of these observations
to arginine content in vascular disease is unknown; however, it should
be noted that these studies were conducted just 2 to 3 days after
diabetes induction. Similar actions have been found by this same group
in human fetal endothelial cells in gestational
diabetes.130
Conclusion. There are too few measurements of NOS
activity, mRNA, and protein in the literature to formulate a consensus.
There is some evidence of increased mRNA and protein despite impaired
endothelial function. These observations suggest that
NO synthesis might be regulated by factors present in the intact
cell under conditions (eg, substrate provision or cofactor
concentration) that may not be optimal for NOS enzyme activity (see
"Discussion").
The reasons for decreased plasma arginine are unclear. One study showed
that plasma arginine was decreased at 14 days.159
This was associated with a larger excretion of arginine with increases
in nitrate/nitrite and cGMP, suggesting that lower plasma arginine
results from increased renal NO production and/or increased
elimination of arginine. Tissue levels of arginine might be decreased
as the plasma arginine concentration in diabetic rats is near the
Km for arginine transport into
endothelial cells and the
Km does not appear to change, at least in
certain tissue and during early stages of
diabetes.129
There is a paucity of information regarding arginine content in
diabetic tissue. Despite increased arginine content in gastric glands
of 2- to 3-day alloxan-diabetic rabbits,20 the
content of arginine in freshly isolated diabetic rat aorta is
reduced.127 If arginine content is in fact
diminished in various vascular tissue in diabetes, then replacement
therapy should improve NO-mediated relaxation. One study showed that
L-arginine partially improved, albeit modestly, basal and
agonist-stimulated cGMP in diabetic glomeruli.154
Incubation in vitro with L-arginine but not
D-arginine augments relaxation to acetylcholine but not to
nitroglycerin in both
streptozotocin138 174 and BB
diabetic180 rat aorta. The fact that
L-arginine supplementation increased NOS
inhibitor–sensitive, acetylcholine-stimulated cGMP
production, but not nitroglycerin-stimulated
cGMP production, indicates that this effect is specific for
augmenting endogenous NO
synthesis.127 In contrast, in one study
L-arginine did not improve relaxation to acetylcholine in
diabetic rat aorta.180 It is difficult to
reconcile these opposite findings because the duration of disease,
species, and artery type were similar. Differences in experimental
design and protocols, arginine concentration, and duration of arginine
exposure may explain these varied findings. For example, in the study
in which arginine had no effect,181 arginine was
given between the second and third challenges to acetylcholine. It
would be interesting to know whether multiple challenges in vitro in
arginine-free buffers with agents that stimulate NO release further
deplete the reservoir of arginine in diabetic tissue such that reversal
by L-arginine becomes more resistant.
It has been suggested99 182 that the beneficial
effects of L-arginine are specific to isolated preparations
and due to a theoretical depletion of tissue arginine, since arginine
is not normally present in the buffers used for in vitro vascular
function studies. This hypothesis is based on an earlier
study183 and is confirmed
elsewhere,184 wherein arginine content decreases
rather rapidly in endothelial cells cultured under
arginine-free conditions. This possibility cannot yet be excluded for
the various in vitro diabetic vascular studies because this has not yet
been tested. This hypothesis has been challenged8
because dysfunction occurs in animals and humans at
physiological arginine concentrations.
There are several points that mitigate against the in vitro hypothesis.
First, while incubation of porcine aortic endothelial
cells in arginine-free media results in depletion of arginine content,
this phenomenon apparently does not occur in all types of
endothelial cells, even for durations of up to 24 hours
of arginine-free conditions.185 Therefore, it
cannot be automatically assumed that arginine depletion in
endothelial cells occurs in all intact artery
preparations in vitro. Second, if the endothelial
dysfunction seen in diabetic arteries tested in vitro is merely due to
the absence of arginine in the buffer, it is difficult to reconcile why
one does not always observe diminished relaxation in all studies and to
all endothelium-dependent vasodilators that also act
via NO. Indeed, in the absence of arginine-supplemented buffer,
receptor-independent, endothelium-dependent relaxation
to the calcium ionophore A23187 in aorta that is normally blocked fully
by NOS inhibitors is not diminished in either
streptozotocin-induced137 or genetically prone BB
diabetic rats.33 Third, tissue arginine content
in diabetic rat aorta is decreased despite the fact that samples were
freshly extracted from animals (ie, without extended incubation in
arginine-free media). Fourth, arginine content in isolated
coronary endothelial cells of the diabetic BB
rat was normal or even slightly elevated, yet these same cells
demonstrated defective NO synthesis based on both nitrite release into
media and arginine-to-citrulline conversion
analysis.172 These studies also showed
that NOS activity in cell homogenates was normal,
suggesting impaired arginine utilization under intact cell conditions.
Fifth, acetylcholine-stimulated relaxation of diabetic canine
coronary arteries was decreased in vivo but not in
vitro,107 and addition of L-arginine
to diabetic canine coronary arteries in vitro did not enhance
the diminished acetylcholine-stimulated cGMP
production.107 In contrast, in other
studies, intracoronary infusion of L-arginine
infusion in diabetic dog hearts improved
endothelium-dependent
relaxation,20 and in situ application of
L-arginine improved nerve blood flow in the
rat.186
These observations would argue against effects of
L-arginine that are unique to the in vitro studies and
unique to the rat model. Interestingly, effects in the diabetic dog in
vivo occurred despite normal plasma arginine concentrations, suggesting
that static plasma arginine levels need not be reduced for there to be
improvement in endothelial function by
L-arginine administration. Why this occurs is unknown. One
possibility is that arginine transport might be reduced directly by
elevated glycated proteins in the blood.187
There are reports that appear not to support the concept of defects in
L-arginine utilization. In one case, topical application of
L-arginine apparently did not improve relaxation in basilar
artery of streptozotocin-induced diabetic
rats,188 in cheek pouch microcirculation of
diabetic hamsters,189 or in mesenteric artery of
BB diabetic rats.34 Additional information is
needed to determine with total certainty whether these studies reflect
important regional differences in the beneficial action of
L-arginine on reversal of diabetic
endothelial dysfunction because of differences in
arginine concentration, duration of exposure, location of application,
and duration of disease (see "Discussion") and the potential for
crossover effects due to multiple agonist challenges in the same
preparation in at least two of these
studies.34 189 In addition, the ineffectiveness
of L-arginine in mesenteric arteries of BB rats is
inconclusive, since a short incubation period was used as well as a
concentration (ie, 10 µmol/L) that is 20 times lower than the
physiological concentration of arginine in rat
plasma and 10 times lower than the Km of
arginine transport into endothelial
cells.129 Furthermore, the potential of masking
by crossover effects due to multiple agonist administration has not
been excluded in these studies.
One should not discount the possibility that progressive changes in
pathology may make endothelial dysfunction
resistant to modification by L-arginine
administration. Indeed, arginine has been shown to be beneficial in
short-term190 but not long-term
atherosclerosis.191 Indeed,
L-arginine administration in vitro restores
endothelium-dependent relaxation after 8 weeks of
diabetes but not after 12 weeks of diabetes in aorta of Lewis-strain
diabetic rats.174 It may be noteworthy to
consider the possibility that the negative results of topical
application of L-arginine in situ in basilar arteries were
observed in animals of 12-week disease duration. Currently, there is no
information whether duration of disease alters arginine transport
kinetics.
Transport kinetics into vascular smooth muscle cells during topical
application of arginine in diabetic arteries is another consideration.
This initial uptake must be sufficient to optimize intracellular
arginine at a concentration adequate to facilitate subsequent uptake by
diabetic endothelium. It was presumed that the
concentration of arginine that failed to augment relaxation in diabetic
rat basilar artery and hamster cheek pouch microcirculation was
adequate on the basis of improved relaxation in basilar artery of
hypertensive rats192 and in cheek pouch of
cardiomyopathic hamsters193 using
a similar arginine concentration. It is possible that the concentration
and time of exposure and alterations in transport into vascular smooth
muscle are complications that need to be considered for diabetic
tissue. Indeed, in studies conducted within the same
species,194 the Km
for transport into smooth muscle cells is much lower (ie, 25 µmol/L)
compared with that for endothelial cells (ie,
Alternatively, protein kinase C (PKC) is known to be increased in
diabetic rat aorta and heart195 196 and in
vascular smooth muscle cells exposed to elevated glucose
concentrations.196 Furthermore, PKC
inhibitors normalize relaxation in the cerebral arteries of
diabetic or hyperglycemic rats.80 197 PKC
activation is known to markedly reduce arginine transport in normal rat
vascular smooth muscle cells.198 Thus, these
alternative hypotheses should be addressed before final conclusions can
be drawn regarding regional differences in efficacy of arginine to
restore endothelial function.
The efficacy of arginine in diabetic kidney seems less in doubt. The
hyperfiltration and proteinuria produced in short-term diabetes in rats
was prevented by dietary arginine
supplementation.158 Paradoxically, this was
associated with a reversal of the enhanced urinary excretion of
nitrate/nitrite and cGMP, suggesting that dietary arginine represses
the augmented renal production of NO at early stages of the
disease. In 2-month diabetic rats, arginine modestly improved the
decreased basal and agonist-stimulated cGMP in glomeruli but not to
control levels (cGMP). Interestingly, with slightly longer disease
duration, arginine failed to alter the decreased basal and
agonist-stimulated NO as measured by the NO
electrode,199 which is in agreement with temporal
studies in diabetic rat aorta.174
Conclusion. There is increasing evidence both in vivo
and in vitro that arginine can improve endothelial
dysfunction and NO production in diabetes. Because of certain
methodological considerations, additional studies are warranted to
determine whether there are important regional differences in vascular
response to arginine and whether arginine will be efficacious at
various stages of the disease.
To circumvent this limitation, one study in patients with uncomplicated
IDDM revealed that arginine treatment augmented plasma cGMP levels and
L-citrulline levels to a similar extent in both control and
IDDM patients.178 This is consistent with
data showing that arginine supplementation improves
endothelium-dependent relaxation in
NIDDM.207 In contrast, high concentrations of
L-arginine had no effect in IDDM
patients.208 Arginine has also been shown in
NIDDM patients but not healthy controls to enhance insulin-mediated
dilation.209
Conclusion. While positive results indicate that
arginine may reverse NO deficits in humans, additional studies are
required to confirm or refute these initial findings.
In diabetic rat aorta, the improvement in relaxation to acetylcholine
by L-arginine could be elicited despite coadministration of
either TEA, indomethacin, or
catalase.127 This suggests that enhanced
K+ channel activity, vasodilator
prostaglandins, and
H2O2 cannot account for the
beneficial effects of L-arginine. More recent studies using
glibenclamide suggest that L-arginine also does not improve
relaxation via enhanced KATP-mediated relaxation
(G.M.P., unpublished observations, 1997). It is not possible to
conclude that similar results will be obtained in other arteries and
species, since a comprehensive analysis has not been
forthcoming. We do note that the beneficial effects of
L-arginine in diabetic canine coronaries occurred despite
the fact that all animals were treated with aspirin to inhibit
cyclooxgenase activity.20
In diabetic canine coronary arteries and in diabetic rat aorta,
restoration of endothelial function by
L-arginine cannot be accounted for by altered prostacyclin
production or enhanced K+ channel
activity. Combined with the data showing augmented cGMP generation,
this suggests that the effects of arginine in diabetes are specific for
enhanced NO activity.
In another study, incubation of normal rat mesenteric arteries with
elevated glucose concentrations in vitro caused impaired relaxation to
acetylcholine.79 Addition of 0.1 mmol/L
L-arginine abrogated the effect of 20 mmol/L glucose
and significantly reduced the detrimental effects of 45 mmol/L
glucose. Another study showed that glucose-induced decrease in
Na+,K+-ATPase of normal
rabbit aorta was also prevented by coincubation with
L-arginine.214
The direct effects of glucose have also been examined in hyperglycemic
clamp experiments in leg blood flow of healthy
subjects.76 The decreased blood flow observed
after 60 and 90 minutes of hyperglycemia was completely reversed by
L-arginine. The fact that neither D-arginine or
L-lysine was effective illustrates the selectivity and
specificity for the L-arginine action.
Conclusion. Arginine appears to provide protection from
alterations in vascular function caused by elevated glucose
concentration. The mechanism of this protection is still unknown.
L-Arginine also reduces collagen accumulation in diabetic
mice218 219 and in basement membrane
thickening220 and advanced stage glycosylation
end products (AGEs).220 221 This presumably
happens because protein cross-linking involves lysine-like residues
that may be competed for by exogenous arginine. Indeed,
L-arginine can directly inhibit AGE product formation
initiated in vitro.221 Because AGEs are believed
to quench NO,70 arginine administration might be
of benefit to improve endothelium-dependent relaxation
by preventing AGE-mediated quenching of NO-dependent relaxation.
The observation that short-term oral administration of arginine
restores endothelial dysfunction via
NO151 suggests that it is not obligatory that
arginine alter basement membrane defects or AGE products to provide
this protection. Certainly, glycosylated hemoglobin is not altered by
this intervention, and neither are plasma glucose
levels.151 This suggests that short-term
administration of oral arginine may produce benefits independent of
glycemic control, insulin secretion, and protein glycation. Perhaps
this results from replenishment of diminished arginine stores in
diabetic vascular tissue, as has been recently
demonstrated,127 and/or from an increase in the
scavenging of superoxide anion radicals due to enhanced NO
production.
Conclusion. On the basis of the present experimental
evidence, there are several potential pathways by which dietary
arginine supplementation in vivo might benefit the diabetic
endothelium. This suggests that experimentation using
this modality of intervention may be an area of investigation in the
prevention or improvement of vascular endothelial
dysfunction in diabetes mellitus.
Received October 15, 1997;
first decision November 13, 1997;
accepted December 2, 1997.
2.
Kubes P, Suzuki M, Granger DN. Nitric oxide: an
endogenous modulator of leukocyte adhesion. Proc Natl
Acad Sci U S A. 1991;88:4651–4655.
3.
Garg UC, Hassid S. Nitric oxide-generating
nitrovasodilators and 8-bromo-cyclic guanosine monophosphate inhibit
mitogenesis and proliferation of cultured rat vascular smooth muscle
cells. J Clin Invest. 1989;83:1774–1777.
4.
Palmer RMJ, Ashton DS, Moncada S. Vascular
endothelial cells synthesize nitric oxide from
L-arginine. Nature. 1988;333:694–666.
5.
Pieper GM, Gross GJ. Endothelial
dysfunction in diabetes. In: Rubanyi GM, ed.
Cardiovascular Significance of
Endothelium-Derived Vasoactive Factors. Mount
Kisco, NY: Futura Publishing; 1991:223–249.
6.
Kamata N, Miyata N, Abiru T, Kasuya Y. Functional
changes in vascular smooth muscle and endothelium of
arteries during diabetes mellitus. Life Sci. 1992;50:1379–1387.[Medline]
[Order article via Infotrieve]
7.
Cohen RA. Dysfunction of vascular
endothelium in diabetes mellitus.
Circulation. 1993;87(suppl V):V-67–V-76.
8.
Poston L, Taylor PD.
Endothelium-mediated vascular function in
insulin-dependent diabetes mellitus. Clin Sci. 1995;88:245–255.[Medline]
[Order article via Infotrieve]
9.
Oyama Y, Kawasaki H, Hattori Y, Kanno M. Attenuation
of endothelium-dependent relaxation in aorta from
diabetic rats. Eur J Pharmacol. 1986;131:75–78.[Medline]
[Order article via Infotrieve]
10.
Pieper GM, Gross GJ. Oxygen free radicals abolish
endothelium-dependent relaxation in diabetic rat aorta.
Am J Physiol. 1988;255:H825–H833.
11.
Gebremedhin D, Koltai MZ, Pogátsa G, Magyar K,
Hadházy P. Influence of experimental diabetes on the mechanical
responses of canine coronary arteries: role of
endothelium. Cardiovasc Res. 1988;22:537–544.[Medline]
[Order article via Infotrieve]
12.
Kamata K, Miyata N, Kasuya Y. Impairment of
endothelium-dependent relaxation and changes in levels
of cyclic GMP in aorta from streptozotocin-induced diabetic rats.
Br J Pharmacol. 1989;97:614–618.[Medline]
[Order article via Infotrieve]
13.
Tesfamariam B, Jakubowski JA, Cohen RA. Contraction
of diabetic rabbit aorta caused by endothelium-derived
PGH2-TxA2. Am J
Physiol. 1989;257:H1327–H1333.
14.
Hattori Y, Kawasaki H, Abe K, Kanno M. Superoxide
dismutase recovers altered endothelium-dependent
relaxation in diabetic rat aorta. Am J Physiol. 1991;261:H1086–H1094.
15.
Cameron NE, Cotter MA. Impaired contraction and
relaxation in aorta from streptozotocin-diabetic rats: role of polyol
pathway. Diabetologia. 1992;35:1011–1019.[Medline]
[Order article via Infotrieve]
16.
Chang KSK, Stevens WC.
Endothelium-dependent increase in vascular sensitivity
to phenylephrine in long-term streptozotocin diabetic rat
aorta. Br J Pharmacol. 1992;107:983–990.[Medline]
[Order article via Infotrieve]
17.
Otter DJ, Chess-Williams R. The effects of aldose
reductase inhibition with ponalrestat on changes in vascular function
in streptozotocin diabetic rats. Br J Pharmacol. 1994;113:576–580.[Medline]
[Order article via Infotrieve]
18.
Kamata K, Sugiura M, Kojima S, Kasuya Y. Preservation
of endothelium-dependent relaxation in
cholesterol-fed and streptozotocin-induced diabetic mice by
the chronic administration of cholestyramine. Br J
Pharmacol. 1996;118:385–391.[Medline]
[Order article via Infotrieve]
19.
Abiru T, Watanabe Y, Kamata K, Miyata N, Kasuya Y.
Decrease in endothelium-dependent relaxation and levels
of cyclic nucleotides in aorta from rabbits with
alloxan-induced diabetes. Res Commun Chem Pathol Pharmacol. 1990;68:13–25.[Medline]
[Order article via Infotrieve]
20.
Matsunaga T, Okumura K, Ishizaka H, Tsunoda R, Tayama
S, Tabuchi T, Yasue H. Impairment of coronary blood flow
regulation by endothelium-derived nitric oxide in dogs
with alloxan-induced diabetes. J Cardiovasc Pharmacol. 1996;28:60–67.[Medline]
[Order article via Infotrieve]
21.
Mayhan WG, Simmons LK, Sharpe GM. Mechanism of
impaired responses of cerebral arterioles during diabetes mellitus.
Am J Physiol. 1991;260:H319–H326.
22.
Takiguchi Y, Satoh N, Hashimoto H, Nakashima M.
Changes in vascular reactivity in experimental diabetic rats:
comparison with hypothyroid rats. Blood Vessels. 1988;25:250–260.[Medline]
[Order article via Infotrieve]
23.
Pelligrino DA, Miletich DJ, Albrecht RF. Diminished
muscarinic receptor-mediated cerebral blood flow response in
streptozotocin-treated rats. Am J Physiol. 1992;262:E447–E454.
24.
Taylor PD, Graves JE, Poston L. Selective impairment
of acetylcholine-mediated endothelium-dependent
relaxation in isolated resistance arteries of the
streptozotocin-induced diabetic rat. Clin Sci. 1995;88:519–524.[Medline]
[Order article via Infotrieve]
25.
Diederich D, Skopec J, Diederich A, Dai FX.
Endothelial dysfunction in mesenteric resistance
arteries of diabetic rat: role of free radicals. Am J
Physiol. 1994;266:H1153–H1161.
26.
Rösen P, Ballhausen T, Bloch W, Addicks K.
Endothelial relaxation is disturbed by oxidative stress
in the diabetic rat: influence of tocopherol as
antioxidant. Diabetologia. 1995;38:1157–1168.[Medline]
[Order article via Infotrieve]
27.
Ralevic V, Belai A, Burnstock G. Effects of
streptozotocin-diabetes on sympathetic nerve,
endothelial and smooth muscle function in the rat
mesenteric arterial bed. Eur J Pharmacol. 1995;286:193–199.[Medline]
[Order article via Infotrieve]
28.
Hill MA, Ege EA. Active and passive mechanical
properties of isolated arterioles from STZ-induced diabetic rats:
effect of aminoguanidine treatment. Diabetes. 1994;43:1450–1456.[Abstract]
29.
Bertuglia S, Malandrino S, Colantuoni A. Effects of
the natural flavonoid delphinidin on diabetic microangiopathy.
Arzneim Forsch/Drug Res. 1995;45:481–485.[Medline]
[Order article via Infotrieve]
30.
Lash JM, Bohlen HG. Structural and functional origins
of suppressed acetylcholine vasodilation in diabetic rat intestinal
arterioles. Circ Res. 1991;69:1259–1268.
31.
Meraji S, Jayakody L, Senaratne MPJ, Thomson ABR,
Kappagoda T. Endothelium-dependent relaxation in aorta
of BB rat. Diabetes. 1987;36:978–981.[Abstract]
32.
Durante W, Sen AK, Sunahara FA. Impairment of
endothelium-dependent relaxation in aortae from
spontaneously diabetic rats. Br J Pharmacol. 1988;94:463–468.[Medline]
[Order article via Infotrieve]
33.
Pieper GM, Moore-Hilton G, Roza AM. Evaluation of the
mechanism of endothelial dysfunction in the genetically
diabetic BB rat. Life Sci. 1996;58:147–152.
34.
Heygate KM, Lawrence IG, Bennett MA, Thurston H.
Impaired endothelium-dependent relaxation in isolated
resistance arteries of spontaneously diabetic rats. Br J
Pharmacol. 1995;116:3251–3259.[Medline]
[Order article via Infotrieve]
35.
Lindsay RM, Peet RS, Wilkie GS, Rossiter SP, Smith W,
Baird JD, Williams BC. In vivo and in vitro evidence of altered nitric
oxide metabolism in the spontaneously diabetic,
insulin-dependent BB/Edinburgh rat. Br J Pharmacol. 1997;120:1–6.[Medline]
[Order article via Infotrieve]
36.
Miyata N, Tsuchida K, Okuyama S, Otomo K, Kamata K,
Kasuya Y. Age-related changes in endothelium-dependent
relaxation in aorta from genetically diabetic WBN/Kob rats.
Am J Physiol. 1992;262:H1104–H1109.
37.
Miyata N, Yamaura H, Tsuchida K, Okuyama S, Otomo S,
Kamata K, Kasuya Y. Impairment of endothelium-dependent
relaxation of superior mesenteric artery in genetically diabetic
WBN/Kob rats. Can J Physiol Pharmacol. 1993;71:297–300.[Medline]
[Order article via Infotrieve]
38.
Bohen HG, Lash JM.
Endothelial-dependent vasodilation is preserved in
non-insulin-dependent Zucker fatty diabetic rats. Am J
Physiol. 1995;268:H2366–H2374.
39.
Sexl V, Mancusi G, Raberger G, Schütz W.
Age-related changes in vascular reactivity in genetically diabetic
rats. Pharmacology. 1995;50:238–246.[Medline]
[Order article via Infotrieve]
40.
Turner NC, White P. Effects of streptozotocin-induced
diabetes on vascular reactivity in genetically
hyperinsulinaemic obese Zucker rats. J
Cardiovasc Pharmacol. 1996;27:884–890.[Medline]
[Order article via Infotrieve]
41.
McNamee CJ, Kappagoda CT, Kunjara R, Russell JC.
Defective endothelium-dependent relaxation in the
JCR:LA-corpulent rat. Circ Res. 1994;74:1126–1132.
42.
Saenz de Tejada I, Goldstein I, Azadzoi K, Krane RJ,
Cohen RA. Impaired neurogenic and endothelium-mediated
relaxation of penile smooth muscle from diabetic men with impotence.
N Engl J Med. 1989;320:1025–1030.[Abstract]
43.
Nitenberg A, Valensi P, Sachs R, Dali M, Aptecar E,
Attali J-R. Impairment of coronary vascular reserve and
ACh-induced coronary vasodilation in diabetic patients with
angiographically normal coronary arteries and normal left
ventricular systolic function. Diabetes. 1993;42:1017–1025.[Abstract]
44.
Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee
BK, Creager MA. Impaired endothelium-dependent
vasodilation in patients with insulin-dependent diabetes mellitus.
Circulation. 1993;88:2510–2516.
45.
McNally PG, Watt PAC, Rimmer T, Burden AC, Hearnshaw
JR, Thurston H. Impaired contraction and
endothelium-dependent relaxation in isolated resistance
vessels from patients with insulin dependent diabetes mellitus.
Clin Sci. 1994;87:31–36.[Medline]
[Order article via Infotrieve]
46.
Mäkimattila S, Virkamäki A, Groop P-H,
Cockcroft J, Utriainen T, Fagerudd J, Yki-Järvinen H. Chronic
hyperglycemia impairs endothelial function and insulin
sensitivity via different mechanisms in insulin-dependent diabetes
mellitus. Circulation. 1996;94:1276–1282.
47.
O'Driscoll G, Green D, Rankin J, Stanton K, Taylor
R. Improvement in endothelial function by
angiotensin converting enzyme inhibition in
insulin-dependent diabetes mellitus. J Clin Invest. 1997;100:678–684.[Medline]
[Order article via Infotrieve]
48.
McVeigh GE, Brennan GM, Johnston GD, McDermott BJ,
McGrath LT, Henry WR, Andrews JW, Hayes JR. Impaired
endothelium-dependent and independent vasodilation in
patients with type 2 (non-insulin-dependent) diabetes mellitus.
Diabetologia. 1992;35:771–776.[Medline]
[Order article via Infotrieve]
49.
Morris SJ, Shore AC, Tooke JE. Responses of the skin
microcirculation to acetylcholine and sodium nitroprusside in patients
with NIDDM. Diabetologia. 1995;38:1337–1344.[Medline]
[Order article via Infotrieve]
50.
Watts GF, O'Brien SF, Silvester W, Millar JA.
Impaired endothelium-dependent and -independent
dilatation of forearm resistance arteries in men with diet-treated
non-insulin-dependent diabetes: role of dyslipidaemia. Clin
Sci. 1996;91:567–573.[Medline]
[Order article via Infotrieve]
51.
Karasu Ç, Soncul H, Altan VM. Effects of
non-insulin dependent diabetes mellitus on the reactivity of human
internal mammary artery and human saphenous vein. Life Sci. 1995;57:103–112.[Medline]
[Order article via Infotrieve]
52.
Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P,
Creager MA. Vitamin C improves endothelium-dependent
vasodilation in patients with non-insulin-dependent diabetes mellitus.
J Clin Invest. 1996;97:22–28.[Medline]
[Order article via Infotrieve]
53.
Steinberg HO, Chaker H, Leaming R, Johnson A,
Brechtel G, Baron AD. Obesity/insulin resistance is associated with
endothelial dysfunction: implications for the syndrome
of insulin resistance. J Clin Invest. 1996;97:2601–2610.[Medline]
[Order article via Infotrieve]
54.
Calver A, Collier J, Vallance P. Inhibition and
stimulation of nitric oxide synthesis in the human forearm
arterial bed of patients with insulin-dependent diabetes.
J Clin Invest. 1992;90:2548–2554.
55.
Smits P, Kapma J-A, Jacobs M-C, Lutterman J, Thien T.
Endothelium-dependent vascular relaxation in patients
with type I diabetes. Diabetes. 1993;42:148–153.[Abstract]
56.
Elliott TG, Cockcroft JR, Groop P-H, Viberti GC,
Ritter JM. Inhibition of nitric oxide synthesis in forearm vasculature
of insulin-dependent diabetic patients: blunted vasoconstriction in
patients with microalbuminuria. Clin Sci. 1993;85:687–693.[Medline]
[Order article via Infotrieve]
57.
Avogara A, Piarulli F, Valerio A, Miola M, Calveri M,
Pavan P, Vicini P, Cobelli C, Tiengo A, Calo, Del Prato S. Forearm
nitric oxide balance, vascular relaxation, and glucose
metabolism in NIDDM patients. Diabetes. 1997;46:1040–1046.[Abstract]
58.
Cipolla MJ, Harker CT, Porter JM.
Endothelial function and adrenergic reactivity in human
type-II diabetic resistance arteries. J Vasc Surg. 1996;23:940–949.[Medline]
[Order article via Infotrieve]
59.
Schaper NC, Houben AJHM, Schoon Y, Kooman JP, Huvers
FC, Niewenhuijzen-Kruseman AC. Venous compliance and the venodilatory
effect of nitroglycerin in insulin-dependent diabetic
patients with and without (incipient) nephropathy.
Eur J Clin Invest. 1994;24:382–387.[Medline]
[Order article via Infotrieve]
60.
Goodfellow J, Ramsey MW, Luddington LA, Jones CJH,
Coates PA, Dunstan F, Lewis MJ, Owens DR, Henderson AH.
Endothelium and inelastic arteries: an early marker of
vascular dysfunction in non-insulin dependent diabetes. Br
Med J. 1996;312:744–745.
61.
Lambert J, Aarsen M, Donker AJM, Stehouwer CDA.
Endothelium-dependent and -independent vasodilation of
large arteries in normoalbuminuric insulin-dependent diabetes
mellitus. Arterioscler Thromb Vasc Biol. 1996;16:705–711.
62.
Clarkson P, Celermajer DS, Donald AE, Sampson M,
Sorensen KE, Adams M, Yue DK, Betteridge DJ, Deanfield JE. Impaired
vascular reactivity in insulin-dependent diabetes mellitus is related
to disease duration and low density lipoprotein cholesterol
levels. J Am Coll Cardiol. 1996;28:573–579.[Abstract]
63.
Zenere BM, Arcaro G, Saggiani F, Rossi L, Muggeo M,
Lechi A. Noninvasive detection of functional alterations of the
arterial wall in IDDM patients with and without
microalbuminuria. Diabetes Care. 1995;18:975–982.[Abstract]
64.
Huvers FC, Schaper NC, Houben AJHM, Hofstra L,
Kitslaar PJEHM, DeLeeuw PW, Niewenhuijzen Kruseman AC. Impaired
arterial but not venous responsiveness to
nitroglycerin in non-insulin-dependent diabetes
mellitus. Eur J Clin Invest. 1997;27:360–365.[Medline]
[Order article via Infotrieve]
65.
McVeigh G, Brennan G, Hager R, Johnston D. Primary
nitrate tolerance in diabetes mellitus. Diabetologia. 1994;37:115–117.[Medline]
[Order article via Infotrieve]
66.
Lekakis J, Papamichael C, Anastasiou H, Alevizaki M,
Desses N, Souvatzoglou A, Stamatelopoulous S, Koutras DA.
Endothelial dysfunction of conduit arteries in
insulin-dependent diabetes mellitus without
microalbuminuria. Cardiovasc Res. 1997;34:164–168.
67.
Ewald U, Kobbah M, Tuvemo T. Vascular reactivity and
platelet aggregability during the first five years of
insulin-dependent diabetes in children. Acta Pædiatr.
1997;suppl 418:15–20.
68.
Giugliano D, Marfella R, Verrazzo G, Acampora R,
Donzella C, Quatraro A, Coppola L, D'Onofrio F. Abnormal rheologic
effect of glyceryl trinitrate in patients with non-insulin-dependent
diabetes mellitus and reversal by antioxidants. Ann Intern
Med. 1995;123:338–343.
69.
Miyoshi H, Nakaya Y, Moritoki H.
Nonendothelial-derived nitric oxide activates
the ATP-sensitive K+ channel of vascular smooth
muscle. FEBS Lett. 1994;345:47–49.[Medline]
[Order article via Infotrieve]
70.
Bucala R, Tracey KJ, Cerami A. Advanced glycosylation
products quench nitric oxide and mediate defective
endothelium-dependent vasodilatation in experimental
diabetes. J Clin Invest. 1991;87:432–438.
71.
Rodríguez-Mañas L, Arribas S,
Girón C, Villamor J, Sánchez-Ferrer CF, Marín
J. Interference of glycosylated human hemoglobin with
endothelium-dependent responses.
Circulation. 1993;88:2111–2116.
72.
Oltman CL, Gutterman DD, Scott EC, Bocker JM,
Dellsperger KC. Effects of glycosylated hemoglobin on vascular
responses in vitro. Cardiovasc Res. 1997;34:179–184.
73.
Duckrow RB. Decreased cerebral blood flow during
acute hyperglycemia. Brain Res. 1995;703:145–150.[Medline]
[Order article via Infotrieve]
74.
Cipolla MJ, Porter JM, Osol G. High glucose
concentrations dilate cerebral arteries and diminish myogenic tone
through an endothelial mechanism. Stroke. 1997;28:405–411.
75.
Wascher TC, Bachernegg M, Kickenweiz A, Stark G,
Stark U, Toplak H, Graier WF. Involvement of the L-arginine-nitric
oxide pathway in hyperglycaemia-induced coronary artery
dysfunction of isolated guinea pig hearts. Eur J Clin
Invest. 1996;26:707–712.[Medline]
[Order article via Infotrieve]
76.
Guigliano D, Marfella R, Coppola L, Verrazzo G,
Acampora R, Giunta R, Nappo F, Lucarelli C, D'Onofrio F. Vascular
effects of acute hyperglycemia in humans are reversed by
L-arginine: evidence for reduced availability of nitric
oxide during hyperglycemia. Circulation. 1997;95:1783–1790.
77.
Tesfamariam B, Cohen RA. Free radicals mediate
endothelial cell dysfunction caused by elevated
glucose. Am J Physiol. 1992;263:H321–H326.
78.
Bohlen HG, Lash JM. Topical hyperglycemia rapidly
suppresses EDRF-mediated vasodilation of normal rat arterioles.
Am J Physiol. 1993;265:H219–H225.
79.
Taylor PD, Poston L. The effect of hyperglycaemia on
function of rat isolated mesenteric resistance artery. Br J
Pharmacol. 1994;113:801–808.[Medline]
[Order article via Infotrieve]
80.
Mayhan WG, Patel KP. Acute effects of glucose on
reactivity of cerebral microcirculation: role of protein kinase C.
Am J Physiol. 1995;269:H1297–H1302.
81.
Dorigo P, Fraccarollo D, Santostasi G, Maragno I.
Impairment of endothelium-dependent but not
endothelium-independent dilatation in guinea pig aorta
rings incubated in the presence of elevated glucose. Br J
Pharmacol. 1997;121:972–976.[Medline]
[Order article via Infotrieve]
82.
Houben AJHM, Schaper NC, De Haan CHA, Huvers FC,
Slaaf DW, DeLeeuw PW, Niewenhuijzen-Kruseman AC. Local 24-hr
hyperglycemia does not affect endothelium-dependent or
-independent vasoreactivity in humans. Am J Physiol. 1996;270:H2014–H2020.
83.
Akbari C, Saouaf R, Barnhill D, Newman P, Logerfo F.
Endothelium-dependent vasodilatation is impaired during
acute hyperglycemia. Diabetes. 1997;46(suppl 1):114A.
Abstract.
84.
Sobrevia L, Nadal A, Yudilevich DL, Mann GE.
Activation of L-arginine transport (system y+)
and nitric oxide synthase by elevated glucose and insulin in human
endothelial cells. J Physiol. 1996;490:775–781.
85.
Graier WF, Wascher TC, Lackner L, Toplak H, Krejs GJ,
Kukovetz WF. Exposure to elevated D-glucose concentration modulates
vascular endothelial cell vasodilatatory responses.
Diabetes. 1993;42:1497–1505.[Abstract]
86.
Pieper GM, Dondlinger L. Glucose elevations alter
bradykinin-stimulated intracellular calcium accumulation in cultured
endothelial cells. Cardiovasc Res. 1997;34:169–178.
87.
Magill SB, Dananberg J. Effects of hyperglycemia on
vascular endothelium nitric oxide
metabolism. In: Sowers JR, ed. Contemporary
Endocrinology: Endocrinology of the Vasculature. Totowa, NJ:
Humana Press Inc; 1996:145–156.
88.
Salameh A, Dhein S. Influence of chronic high
D-glucose exposure and long-term-blocker treatment on intracellular
calcium concentrations of porcine aortic endothelial
cells. Diabetes. 1998;47:407–413.[Abstract]
89.
Kiff RJ, Gardiner SM, Comptom AM, Bennett T.
Selective impairment of hindquarter vasodilator responses to bradykinin
in conscious Wistar rats with streptozotocin-induced diabetes mellitus.
Br J Pharmacol. 1991;103:1357–1362.[Medline]
[Order article via Infotrieve]
90.
Alsip NL, Schuschke DA, Miller FN. Microvascular
responses in the skeletal muscle of the diabetic rat. J Lab
Clin Med. 1996;128:429–437.[Medline]
[Order article via Infotrieve]
91.
Wang SP, West MW, Dresner LS, Fleishhacker JF,
Distant DA, Mueller CM, Wait RB. Effects of diabetes and uremia on
mesenteric vascular reactivity. Surgery. 1996;120:328–336.[Medline]
[Order article via Infotrieve]
92.
Mulhern M, Docherty JR. Effects of experimental
diabetes on the responsiveness of rat aorta. Br J
Pharmacol. 1989;97:1007–1012.[Medline]
[Order article via Infotrieve]
93.
Wakabayashi I, Hatake K, Kimura N, Kakishita E, Nagai
K. Modulation of vascular tonus by the endothelium in
experimental diabetes. Life Sci. 1987;40:643–648.[Medline]
[Order article via Infotrieve]
94.
Murray P, Pitt B, Webb RC. Ramipril prevents
hypersensitivity to phenylephrine in aorta from
streptozotocin-induced diabetic rats. Diabetologia. 1994;37:664–670.[Medline]
[Order article via Infotrieve]
95.
Head RJ, Longhurst PA, Panek RL, Stitzel RE. A
contrasting effect of the diabetic state upon the contractile responses
of aortic preparations from the rat and rabbit. Br J
Pharmacol. 1987;91:275–286.[Medline]
[Order article via Infotrieve]
96.
Furman BL, Sneddon P.
Endothelium-dependent vasodilator responses of the
isolated mesenteric bed are preserved in long-term streptozotocin
diabetic rats. Eur J Pharmacol. 1993;232:29–34.[Medline]
[Order article via Infotrieve]
97.
Jaap AJ, Tooke JE. Pathophysiology of microvascular
disease in non-insulin dependent diabetes. Clin Sci. 1995;89:3–12.[Medline]
[Order article via Infotrieve]
98.
Ditzel J. Oxygen transport impairment in diabetes.
Diabetes. 1976;25(suppl 2):832–838.
99.
Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y,
Kawamura K, Nyengaard JF, Van Den Enden M, Kilo C, Tilton RG.
Hyperglycemic pseudohypoxia and diabetic complications.
Diabetes. 1993;42:801–813.[Abstract]
100.
Allison TB, Bruttig SP, Crass MF III, Eliot RS, Shipp
JC. Reduced high-energy phosphate levels in rat hearts, I: effects of
alloxan diabetes. Am J Physiol. 1976;230:1744–1750.
101.
Santilli SM, Fiegel VD, Knighton DR. Alloxan diabetes
alters the rabbit transarterial wall oxygen gradient.
J Vasc Surg. 1991;18:227–233.
102.
Bhardwaj R, Moore PK. Increased vasodilator response
to acetylcholine of renal blood vessels from diabetic rats.
J Pharm Pharmacol. 1988;40:739–742.[Medline]
[Order article via Infotrieve]
103.
Dai F-X, Diederich A, Skopec J, Diederich D.
Diabetes-induced endothelial dysfunction in
streptozotocin-treated rats: role of prostaglandin
endoperoxides and free radicals. J Am Soc
Nephrol. 1993;4:1327–1336.[Abstract]
104.
Heygate KM, Davies J, Holmes M, James RFL, Thurston H.
The effect of insulin treatment and of islet transplantation on the
resistance artery function in the STZ-induced diabetic rat.
Br J Pharmacol. 1996;119:495–504.[Medline]
[Order article via Infotrieve]
105.
Pieper GM. Alterations in reperfusion-stimulated
prostacyclin release by the diabetic heart. In: Nagano M, Dhalla NS,
eds. The Diabetic Heart. New York, NY: Raven Press
Publishers; 1991:465–483.
106.
Shimizu K, Muramatsu M, Kakegawa Y, Asano H, Toki Y,
Miyazaki Y, Okumura K, Hashimoto H, Ito T. Role of
prostaglandin H2 as an
endothelium-derived contracting factor in diabetic
state. Diabetes. 1993;42:1246–1252.[Abstract]
107.
Koltai MZ, Hadházy P, Pósa I, Kocsis E,
Winkler G, Rösen P, Pogátsa G. Characteristics of
coronary endothelial dysfunction in
experimental diabetes. Cardiovasc Res. 1997;34:157–163.[Medline]
[Order article via Infotrieve]
108.
Fujii K, Soma M, Huang YS, Manku MS, Horrobin DF.
Increased release of prostaglandins from the mesenteric
vascular bed in streptozotocin diabetes. Prog Lipid Res. 1986;25:499–501.
109.
White RE, Carrier GO. Supersensitivity and
endothelium dependency of histamine-induced relaxation
in mesenteric arteries isolated from diabetic rats.
Pharmacology. 1986;33:34–38.[Medline]
[Order article via Infotrieve]
110.
Mayhan WG. Impairment of
endothelium-dependent dilatation of the basilary artery
during diabetes mellitus. Brain Res. 1992;580:297–302.[Medline]
[Order article via Infotrieve]
111.
Gebremedhin D, Koltai M, Pogátsa G, Magyar K,
Hadházy P. Altered responsiveness of diabetic dog renal arteries
to acetylcholine and phenylephrine: role of
endothelium. Pharmacology. 1989;38:177–184.[Medline]
[Order article via Infotrieve]
112.
Kamata K, Kobayashi T. Changes in superoxide dismutase
mRNA expression by streptozotocin-induced diabetes. Br J
Pharmacol. 1996;119:583–589.[Medline]
[Order article via Infotrieve]
113.
Pieper GM, Langenstroer P, Siebeneich W.
Diabetic-induced endothelial dysfunction in rat aorta:
role of hydroxyl radicals. Cardiovasc Res. 1997;34:145–156.
114.
Pieper GM, Mei DA, Langenstroer P, O'Rourke ST.
Bioassay of endothelium-derived relaxing factor in
diabetic rat aorta. Am J Physiol. 1992;263:H676–H680.
115.
Taylor PD, Oon BB, Thomas CR, Poston L. Prevention
by insulin treatment of endothelial dysfunction but
enhanced noradrenaline-induced
contractility in mesenteric resistance arteries from
streptozotocin-induced diabetic rats. Br J Pharmacol. 1994;11:35–41.
116.
Olbrich A, Rösen P, Hilgers R-D, Dhein S.
Fosinopril improves regulation of vascular tone in mesenteric bed of
diabetic rats. J Cardiovasc Pharmacol. 1996;27:187–194.[Medline]
[Order article via Infotrieve]
117.
Rösen P, Ballhausen T, Stockklauser K.
Impairment of endothelium dependent relaxation in the
diabetic rat heart: mechanisms and implications. Diabetes Res
Clin Pract. 1996;31(suppl):S143–S155.
118.
Knock GA, McCarthy AL, Lowy C, Poston L. Association
of gestational diabetes with abnormal maternal vascular
endothelial function. Br J Obstet
Gynaecol. 1997;104:229–234.[Medline]
[Order article via Infotrieve]
119.
Cohen RA, Vanhoutte PM.
Endothelium-dependent
hyperpolarization: beyond nitric oxide and cyclic
GMP. Circulation. 1995;92:3337–3349.
120.
Campbell WB, Gebremedhin D, Pratt PF, Harder DR.
Identification of epoxyeicosatrienoic acids as
endothelium-derived hyperpolarizing factors. Circ
Res. 1996;78:415–423.
121.
Kamata K, Miyata N, Kasuya Y. Functional changes in
potassium channels in aortas from rats with streptozotocin-induced
diabetes. Eur J Pharmacol. 1989;166:319–323.[Medline]
[Order article via Infotrieve]
122.
Glocker S, Quast U. Binding and effects of P1075, an
opener of ATP-sensitive K+ channels, in the aorta
from streptozocin-treated diabetic rats. Naunyn Schmiedebergs
Arch Pharmacol. 1997;356:210–215.[Medline]
[Order article via Infotrieve]
123.
Mayhan WG. Effects of diabetes mellitus on response of
the basilar artery to activation of ATP-sensitive potassium channels.
Brain Res. 1994;636:35–39.[Medline]
[Order article via Infotrieve]
124.
Miyata N, Yamaura H, Tsuchida K, Otomo S, Kamata K,
Kasuya Y. Changes in responsiveness of the aorta to vasorelaxant agents
in genetically diabetic rats: a study in WBN/KOB rats. Life
Sci. 1992;50:1363–1369.[Medline]
[Order article via Infotrieve]
125.
Kersten JR, Brooks LA, Dellsperger KC. Impaired
microvascular response to graded coronary occlusion in diabetic
and hyperglycemic dogs. Am J Physiol. 1995;268:H1667–H1674.
126.
Endo K, Abiru T, Machida H, Kasuya Y, Kamata K.
Endothelium-derived hyperpolarizing factor does not
contribute to the decrease in endothelium-dependent
relaxation in the aorta of streptozotocin-induced diabetic rats.
Gen Pharmacol. 1995;26:149–153.[Medline]
[Order article via Infotrieve]
127.
Pieper GM, Dondlinger LA. Plasma and vascular tissue
arginine are decreased by diabetes: acute arginine supplementation
restores endothelium-dependent relaxation by augmenting
cGMP production. J Pharmacol Exp Ther. 1997;283:684–691.
128.
Kamata K, Hosokawa M. Endothelial
dysfunction in the perfused kidney from the streptozotocin-induced
diabetic rat. Res Commun Mol Pathol Pharmacol. 1997;96:57–70.[Medline]
[Order article via Infotrieve]
129.
Contreras R, Fuentes O, Mann GE, Sobrevia L. Diabetes
and insulin-induced stimulation of L-arginine transport and nitric
oxide synthesis in rabbit isolated gastric glands. J Physiol
(Lond). 1997;498:787–796.
130.
Sobrevia L, Cesare P, Yudilevich DL, Mann GE.
Diabetes-induced activation of system y+ and
nitric oxide synthase in human endothelial cells:
association with membrane hyperpolarization.
J Physiol (Lond). 1995;489:183–192.
131.
Fukao M, Hattori Y, Kanno M, Sakuma I, Kitabake A.
Alterations in endothelium-dependent
hyperpolarization and relaxation in mesenteric
arteries from streptozotocin-induced diabetic rats. Br J
Pharmacol. 1997;121:1383–1391.[Medline]
[Order article via Infotrieve]
132.
Ohishi K, Carmines PK. Superoxide dismutase restores
the influence of nitric oxide on renal arterioles in diabetes mellitus.
J Am Soc Nephrol. 1995;5:1559–1566.[Abstract]
133.
Langenstroer P, Pieper GM. Regulation of spontaneous
EDRF release in diabetic rat aorta by oxygen free radicals.
Am J Physiol. 1992;263:H257–H265.
134.
Sikorski BW, James GM, Glance SD, Hodgson WC, King RG.
Effect of endothelium on diabetes-induced changes in
constrictor responses mediated by 5-hydroxytryptamine
in rat aorta. J Cardiovasc Pharmacol. 1993;22:423–430.[Medline]
[Order article via Infotrieve]
135.
Chang KC, Chung SY, Chong WS, Suh JS, Kim SH, Noh HK,
Seong BW, Ko HJ, Chun KW. Possible superoxide radical-induced
alteration of vascular reactivity in aortas from streptozotocin-treated
rats. J Pharmacol Exp Ther. 1993;266:992–1000.
136.
Abiru T, Kamata K, Kasuya Y. Attenuation of depressor
response induced by platelet activating factor and acetylcholine in
streptozotocin-induced diabetic rats. J Pharmacobiol
Dyn. 1991;14:293–300.[Medline]
[Order article via Infotrieve]
137.
Tada H, Muramatsu I, Nakai T, Kigoshi S, Miyabo S.
Effects of chronic diabetes on the responsiveness to endothelin-1 and
other agents of rat atria and thoracic aorta. Gen Pharmacol. 1994;25:1221–1228.[Medline]
[Order article via Infotrieve]
138.
Pieper GM, Peltier BA. Amelioration by L-arginine of a
dysfunctional arginine/nitric oxide pathway in diabetic
endothelium. J Cardiovasc Pharmacol. 1995;25:397–403.[Medline]
[Order article via Infotrieve]
139.
Pieper GM. Acute amelioration of diabetic
endothelial dysfunction with a derivative of the nitric
oxide synthase cofactor, tetrahydrobiopterin. J Cardiovasc
Pharmacol. 1997;29:8–15.[Medline]
[Order article via Infotrieve]
140.
El-Kashef H. Hyperglycemia increased the
responsiveness of isolated rabbits pulmonary
arterial rings to serotonin.
Pharmacology. 1996;53:151–159.[Medline]
[Order article via Infotrieve]
141.
Omawari N, Dewhurst M, Vo P, Mahmood S, Stevens E,
Tomlinson DR. Deficient nitric oxide responsible for reduced nerve
blood flow in diabetic rats: effects of L-NAME, L-arginine, sodium
nitroprusside and evening primrose oil. Br J Pharmacol. 1996;118:186–190.[Medline]
[Order article via Infotrieve]
142.
Komers R, Allen TJ, Cooper ME. Role of
endothelium-derived nitric oxide in the pathogenesis of
the renal hemodynamic changes of experimental diabetes.
Diabetes. 1994;43:1190–1197.[Abstract]
143.
Fouyas IP, Kelly PAT, Ritchie IM, Whittle IR.
Cerebrovascular responsiveness to
NG-nitro-L-arginine methyl
ester in spontaneously diabetic rats. Br J Pharmacol. 1996;118:243–248.[Medline]
[Order article via Infotrieve]
144.
Kamata K, Kondoh H. Impairment of
endothelium-dependent relaxation of the isolated
basilar artery from streptozotocin-induced diabetic rats. Res
Commun Mol Pathol Pharmacol. 1996;94:239–249.[Medline]
[Order article via Infotrieve]
145.
Lawrence E, Brain SD. Altered microvascular reactivity
to endothelin-1, endothelin-3 and
NG-nitro-L-arginine methyl
ester in streptozotocin-induced diabetes mellitus. Br J
Pharmacol. 1992;106:1035–1040.[Medline]
[Order article via Infotrieve]
146.
Mayer B, Brunner F, Schmidt K. Inhibition of nitric
oxide synthesis by methylene blue. Biochem Pharmacol. 1993;45:367–374.[Medline]
[Order article via Infotrieve]
147.
Wolin MS, Cherry PD, Rodenberg JM, Messina EJ, Kaley
G. Methylene blue inhibits vasodilation of skeletal muscle arterioles
to acetylcholine and nitric oxide via the extracellular generation of
superoxide anion. J Pharmacol Exp Ther. 1990;254:872–876.
148.
Pieper GM, Siebeneich W. Use of a nitronyl nitroxide
to discriminate the contribution of nitric oxide radical in
endothelium-dependent relaxation of control and
diabetic blood vessels. J Pharmacol Exp Ther. 1997;283:138–147.
149.
Pieper GM, Lai CS.
N-Methyl-D-glucamine
dithiocarbamate-Fe2+ discriminates basal vs
agonist-stimulated nitric oxide activity in control vs diabetic rat
aorta. Pharmacologist. 1997;39:52. Abstract.
150.
Tesfamariam B, Palacino JJ, Weisbrod RM, Cohen RA.
Aldose reductase inhibition restores endothelial cell
function in diabetic rabbit aorta. J Cardiovasc
Pharmacol. 1993;21:205–211.[Medline]
[Order article via Infotrieve]
151.
Pieper GM, Siebeneich W, Dondlinger LA. Short-term
oral administration of L-arginine reverses defective
endothelium-dependent relaxation and cGMP generation in
diabetes. Eur J Pharmacol. 1996;317:317–320.[Medline]
[Order article via Infotrieve]
152.
Miller MAW, Morgan RJ, Thompson CS, Mikhailidis DP,
Jeremy JY. Adenylate and guanylate cyclase activity in the
penis and aorta of the diabetic rat: an in vitro study. Br J
Urol. 1994;74:106–111.[Medline]
[Order article via Infotrieve]
153.
Wang Y-X, Brooks DP, Edwards RM. Attenuated
glomerular cGMP production and renal vasodilation
in streptozotocin-induced diabetic rats. Am J Physiol. 1993;264:R952–R956.
154.
Craven PA, Studer RK, DeRubertis FR. Impaired nitric
oxide-dependent cyclic guanosine monophosphate generation in glomeruli
from diabetic rats: evidence for protein kinase C-mediated suppression
of the cholinergic response. J Clin Invest. 1994;93:311–320.
155.
Mattar AL, Fujihara CK, Ribeiro MO, de Nucci G, Zatz
R. Renal effects of acute and chronic nitric oxide inhibition in
experimental diabetes. Nephron. 1996;74:136–143.[Medline]
[Order article via Infotrieve]
156.
Tolins JP, Shultz PJ, Raij L, Brown DM, Mauer SM.
Abnormal renal hemodynamic response to reduced renal
perfusion pressure in diabetic rats: role of NO. Am J
Physiol. 1993;265:F886–F895.
157.
Goor Y, Peer G, Iaina A, Blum M, Wollman Y,
Chernihovsky T, Silverberg D, Cabili S. Nitric oxide in ischaemic acute
renal failure of streptozotocin diabetic rats. Diabetologia. 1996;39:1036–1040.[Medline]
[Order article via Infotrieve]
158.
Bank N, Aynedjian HS. Role of EDRF (nitric oxide) in
diabetic renal hyperfiltration. Kidney Int. 1993;43:1306–1312.[Medline]
[Order article via Infotrieve]
159.
Reyes AA, Karl IE, Kissane J, Klahr S. L-Arginine
administration prevents glomerular hyperfiltration and
decreases proteinuria in diabetic rats. J Am Soc
Nephrol. 1993;4:1039–1045.[Abstract]
160.
Zuccollo A, Navarro M, Prendes GM, Dominguez A,
Catanzaro OL. Effects of HOE 140 on some renal functions in type I
diabetic mice. Arch Physiol Biochem. 1996;104:252–254.[Medline]
[Order article via Infotrieve]
161.
Maree A, Peer G, Iaina A, Blum M, Wollman Y,
Csernihovsky T, Silverberg D, Cabili S. Nitric oxide in
streptozotocin-induced diabetes mellitus in rats. Clin Sci. 1996;90:379–384.[Medline]
[Order article via Infotrieve]
162.
Kwon NS, Lee SH, Choi CS, Kho T, Lee HS. Nitric oxide
generation from streptozotocin. FASEB J. 1994;8:529–533.[Abstract]
163.
Schmetterer L, Findl O, Fasching P, Ferber W, Strenn
K, Breiteneder H, Adam H, Eichler H-G, Wolzt M. Nitric oxide and ocular
blood flow in patients with IDDM. Diabetes. 1997;46:653–658.[Abstract]
164.
Smits P, Hersbach FMRJ, Jansen TLTA, Thien T,
Lutterman JA. Impaired vasodilator response to atrial
natriuretic factor in IDDM. Diabetes. 1993;42:1454–1461.[Abstract]
165.
Schmidt RE, Dorsey DA, McDaniel ML, Corbett JA.
Characterization of NADPH diaphorase activity in rat
sympathetic autonomic ganglia: effect of diabetes and aging.
Brain Res. 1993;617:343–348.[Medline]
[Order article via Infotrieve]
166.
Yagihashi N, Nishida N, Seo HG, Taniguchi N, Yagihashi
S. Expression of nitric oxide synthase in macula densa in
streptozotocin diabetic rats. Diabetologia. 1996;39:793–799.[Medline]
[Order article via Infotrieve]
167.
Vernet D, Cai L, Garban H, Babbitt ML, Murray FT,
Rajfer J, Gonzalez-Cadavid NF. Reduction of penile nitric oxide
synthase in diabetic BB/WORdp (type I) and
BBZ/WORdp (type II) rats with erectile
dysfunction. Endocrinology. 1995;136:5709–5717.[Abstract]
168.
Schönfelder G, John M, Hopp H, Fuhr N, Van Der
Giet M, Paul M. Expression of inducible nitric oxide synthase in
placenta of women with gestational diabetes. FASEB J. 1996;10:777–784.[Abstract]
169.
Choi KC, Kim NH, An MR, Kang DG, Kim SW, Lee J-U.
Alterations of intrarenal renin-angiotensin and nitric
oxide systems in streptozotocin-induced diabetic rats. Kidney
Int. 1997;53(suppl 60):S-23–S-27.
170.
Cosentino F, Hishikawa K, Katusic ZS, Lüscher
TF. High glucose increases nitric oxide synthase expression and
superoxide anion generation in human aortic endothelial
cells. Circulation. 1997;96:25–28.
171.
Mancusi G, Hutter C, Baumgartner-Parzer S, Schmidt K,
Schütz W, Sexl V. High-glucose incubation of human umbilical vein
endothelial cells does not alter expression and
function of G-protein-subunits or of endothelial NO
synthase. Biochem J. 1996;315:281–287.
172.
Wu G, Meininger CJ. Impaired arginine
metabolism and NO synthesis in coronary
endothelial cells of the spontaneously diabetic BB rat.
Am J Physiol. 1995;269:H1312–H1318.
173.
Mans AM, DeJoseph MR, Davis DW, Hawkins RA. Regional
amino acid transport into brain during diabetes: effect of plasma amino
acids. Am J Physiol. 1987;253:E575–E583.
174.
Pieper GM, Jordan M, Adams MB, Roza AM. Syngeneic
pancreatic islet transplantation reverses endothelial
dysfunction in experimental diabetes. Diabetes. 1995;33:1106–1113.[Abstract]
175.
Grill V, Björkman O, Gutniak M, Lindqvist M.
Brain uptake and release of amino acids in nondiabetic and
insulin-diabetic subjects: important role of glutamine release for
nitrogen balance. Metabolism. 1992;41:28–32.[Medline]
[Order article via Infotrieve]
176.
Hagenfeldt L, Dahlquist G, Persson B. Plasma amino
acids in relation to metabolic control in insulin-dependent
diabetic children. Acta Pædiatr Scand. 1989;794:278–282.
177.
Felig P, Marliss E, Ohman JL, Cahill GF Jr. Plasma
amino acid levels in diabetic ketoacidosis. Diabetes. 1970;19:727–729.[Medline]
[Order article via Infotrieve]
178.
Smulders RA, Stehower CDA, Olthof CG, Van Kamp GJ,
Teerlink T, DeVries PMJM, Donker AJM. Plasma endothelin levels and
vascular effects of intravenous L-arginine infusion in
subjects with uncomplicated insulin-dependent diabetes mellitus.
Clin Sci. 1994;87:37–43.[Medline]
[Order article via Infotrieve]
179.
Pieper GM, Adams MB, Roza AM. Pancreas transplantation
reverses endothelial dysfunction in experimental
diabetes mellitus. Surgery. 1998;123:89–95.[Medline]
[Order article via Infotrieve]
180.
Pieper GM, Siebeneich W, Moore-Hilton G, Roza AM.
Reversal by L-arginine of a dysfunctional arginine/nitric oxide pathway
in the endothelium of the genetic diabetic BB rat.
Diabetologia. 1997;40:910–915.[Medline]
[Order article via Infotrieve]
181.
Archibald V, Cotter MA, Keegan A, Cameron NE.
Contraction and relaxation of aortas from diabetic rats: effects of
chronic anti-oxidant and aminoguanidine treatments. Naunyn
Schmiedebergs Arch Pharmacol. 1996;353:584–591.[Medline]
[Order article via Infotrieve]
182.
Tilton RG, Chang K, Hasan KS, Smith SR, Petrash JM,
Misko TP, Moore WM, Currie MG, Corbett JA, McDaniel ML, Williamson JR.
Prevention of diabetic vascular dysfunction by guanidines: inhibition
of nitric oxide synthase versus advanced glycation end-product
formation. Diabetes. 1993;42:221–232.[Abstract]
183.
Preik-Steinhoff H, Zink S, Rösen P, Kelm M.
Transport of L-arginine in arginine-deprived
endothelial cells. Biochem Biophys Res
Commun. 1995;213:447–453.[Medline]
[Order article via Infotrieve]
184.
Arnal JF, Münzel T, Venema RC, James NL, Bai C,
Mitch WE, Harrison DG. Interactions between L-arginine and L-glutamine
change endothelial NO production: an effect
independent of NO synthase substrate availability. J Clin
Invest. 1995;95:2565–2572.
185.
Morgan DML, Baydoun AR. Polyamine transport and
arginine pool size in vascular endothelial cells.
Biochem Soc Trans. 1994;22:387S.[Medline]
[Order article via Infotrieve]
186.
Kihara M, Low PA. Impaired vasoreactivity to nitric
oxide in experimental diabetic neuropathy. Exp
Neurol. 1995;132:180–185.[Medline]
[Order article via Infotrieve]
187.
Graier WR, Simecek S, Wascher TC, Kukovetz WR, Kostner
GM. Bidirectional effects of glycated LDL on
endothelial vascular function. Circulation.
1994;90(suppl I):I-29. Abstract.
188.
Mayhan WG, Didion SP, Patel KP. L-Arginine does not
restore dilatation of the basilar artery during diabetes mellitus.
J Cereb Blood Flow Metab. 1996;16:500–506.[Medline]
[Order article via Infotrieve]
189.
Mayhan WG, Patel KP, Sharpe GM. Effect of L-arginine
on reactivity of hamster cheek pouch arterioles during diabetes
mellitus. Int J Microcirc. 1997;17:107–112.[Medline]
[Order article via Infotrieve]
190.
Girerd V, Hirsch AT, Cooke JP, Dzau VJ, Creager MA.
L-Arginine augments endothelium-dependent vasodilation
in cholesterol-fed rabbits. Circ Res. 1990;67:1301–1308.
191.
Mügge A, Harrison DG. L-Arginine does not
restore endothelial dysfunction in atherosclerotic
rabbit aorta in vitro. Blood Vessels. 1991;28:354–357.[Medline]
[Order article via Infotrieve]
192.
Kitazono T, Faraci FM, Heistad DD.
L-Arginine restores dilator responses of the basilar artery
to acetylcholine during chronic hypertension. Hypertension. 1996;27:893–896.
193.
Mayhan WG, Rubinstein I. Acetylcholine induces
vasoconstriction in the microcirculation of
cardiomyopathic hamsters: reversal by L-arginine.
Biochem Biophys Res Commun. 1992;184:1372–1377.[Medline]
[Order article via Infotrieve]
194.
Durante W, Liao L, Iftikhar I, O'Brien WE, Schafer
AI. Differential regulation of L-arginine transport and
nitric oxide production by vascular smooth muscle and
endothelium. Circ Res. 1996;78:1075–1082.
195.
Inoguchi T, Battan R, Handler E, Sportsman JR, Heath
W, King GL. Preferential elevation of protein kinase C isoform beta II
and diacylglycerol levels in the aorta and heart of diabetic rats:
differential reversibility to glycemic control by islet cell
transplantation. Proc Natl Acad Sci U S A. 1992;89:11059–11063.
196.
Kunisaki M, Bursell S-E, Umeda F, Nawata H, King GL.
Normalization of diacylglycerol-protein kinase C activation by vitamin
E in aorta of diabetic rats and cultured rat smooth muscle cells
exposed to elevated glucose levels. Diabetes. 1994;43:1372–1377.[Abstract]
197.
Pelligrino DA, Koenig HM, Wang Q, Albrecht RF. Protein
kinase C suppresses receptor-mediated pial arteriolar relaxation in the
diabetic rat. Neuroreport. 1994;5:417–420.[Medline]
[Order article via Infotrieve]
198.
Rivera-Correa M, Altieri PI, Escobales N. Parallel
regulation of arginine transport and nitric oxide synthesis by
angiotensin II in vascular smooth muscle cells: role of
protein kinase C. Amino Acids. 1996;11:153–170.
199.
Craven PA, Studer RK, DeRubertis FR. Impaired nitric
oxide release by glomeruli from diabetic rats.
Metabolism. 1995;44:695–698.[Medline]
[Order article via Infotrieve]
200.
Das UN, Mohan IK, Kumar KV, Kumar GS, Sekhar CC.
Beneficial effect of L-arginine in non-insulin dependent diabetes
mellitus: a potential role for nitric oxide. Med Sci Res. 1993;21:669–670.
201.
Schmidt HHHW, Warner TD, Ishii K, Sheng H, Murad F.
Insulin secretion from pancreatic B cells caused by L-arginine-derived
nitrogen oxide. Science. 1992;255:721–723.
202.
Giugliano D, Marfella R, Verrazzo G, Acampora R,
Nappor F, Ziccardi P, Coppola L, D'Onofrio F. L-Arginine for testing
endothelium-dependent vascular functions in health and
disease. Am J Physiol. 1997;273(Endocrinol Metab
36):E606–E612.
203.
Steinberg HO, Brechtel G, Johnson A, Fineberg N,
Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide
dependent: a novel action of insulin to increase nitric oxide release.
J Clin Invest. 1994;94:1172–1179.
204.
Scherrer U, Randin D, Vollenweider P, Vollenweider L,
Nicod P. Nitric oxide release accounts for insulin's vascular effects
in humans. J Clin Invest. 1994;94:2511–2515.
205.
Chen Y-L, Messina EJ. Dilation of isolated skeletal
muscle arterioles by insulin is endothelium dependent
and nitric oxide mediated. Am J Physiol. 1996;270:H2120–H2124.
206.
McKay MK, Hester RL. Role of nitric oxide,
adenosine, and ATP-sensitive potassium channels in
insulin-induced vasodilation. Hypertension. 1996;28:202–208.
207.
Chowienczyk PJ, Barnes DJ, Brett SE, Cockcroft JR,
Viberti GC, Ritter JM. Correction of impaired NO-mediated vasodilation
by L-arginine in non-insulin dependent diabetics.
Endothelium. 1995;3:95S. Abstract.
208.
MacAllister RJ, Calver AL, Collier J, Edwards CM,
Herreros B, Nussey SS, Vallance P. Vascular and hormonal responses to
arginine: provision of substrate for nitric oxide or non-specific
effect? Clin Sci. 1995;89:183–190.[Medline]
[Order article via Infotrieve]
209.
Wascher TC, Graier WF, Dittrich P, Hussain MA,
Bahadori B, Wallner S, Toplak H. Effects of low-dose L-arginine on
insulin-mediated vasodilation and insulin sensitivity. Eur J
Clin Invest. 1997;27:690–695.[Medline]
[Order article via Infotrieve]
210.
Riedel MW, Anneser F, Haberl RL. Different mechanisms
of L-arginine-induced dilation of brain arterioles in normotensive and
hypertensive rats. Brain Res. 1995;671:21–26.[Medline]
[Order article via Infotrieve]
211.
Koller A, Sun D, Messina EJ, Kaley G. L-Arginine
analogues blunt prostaglandin-related dilation of
arterioles. Am J Physiol. 1993;264:H1194–H1199.
212.
Kontos HA, Wei EP. Arginine analogues inhibit
responses mediated by ATP-sensitive K+ channels.
Am J Physiol. 1996;271:H1498–H1506.
213.
Wascher TC, Bachernegg M, Kickenweiz E, Stark G, Stark
U, Toplak H, Graier WF, Krejs GJ. Elevation of D-glucose impairs
coronary artery autoregulation after slight reduction of
coronary flow. Eur J Clin Invest. 1995;25:590–594.[Medline]
[Order article via Infotrieve]
214.
Gupta S, Sussman I, McArthur CS, Tornheim K, Cohen RA,
Ruderman NB. Endothelium-dependent inhibition of
NaKATPase activity in rabbit aorta by hyperglycemia: possible role of
endothelium-derived nitric oxide. J Clin
Invest. 1992;90:727–732.
215.
Lubec B, Hayn M, Kitzmüller E, Vierhapper H,
Lubec G. L-Arginine reduces lipid peroxidation in patients with
diabetes mellitus. Free Radic Biol Med. 1997;22:355–357.[Medline]
[Order article via Infotrieve]
216.
Wascher TC, Posch K, Wallner S, Hermetter A, Kostner
GM, Graier WF. Vascular effects of L-arginine: anything beyond a
substrate for the NO-synthase? Biochem Biophys Res Commun. 1997;234:35–38.[Medline]
[Order article via Infotrieve]
217.
Demiryürek AT, Kennedy S, Wainwright CL,
Wadsworth RM, Kane KA. Influence of nitric oxide on luminol-enhanced
chemiluminescence measured from porcine-stimulated leukocytes.
J Cardiovasc Pharmacol. 1997;30:332–337.[Medline]
[Order article via Infotrieve]
218.
Radner W, Höger H, Lubec B, Salzer H, Lubec G.
L-Arginine reduces kidney collagen accumulation and
N-(carboxymethyl)lysine in the aging NMRI-mouse. J
Gerontol. 1994;49:M44–M46.
219.
Khaidar A, Marx M, Lubec B, Lubec G. L-Arginine
reduces heart collagen accumulation in the diabetic db/db mouse.
Circulation. 1994;90:479–483.
220.
Weninger M, Zi Z, Lubec B, Szalay S, Höger
H, Lubec G. L-Arginine reduces glomerular basement membrane
collagen N-carboxymethyllysine in the diabetic db/db mouse.
Nephron. 1992;62:80–83.[Medline]
[Order article via Infotrieve]
221.
Servetnick DA, Bryant D, Wells-Knecht KJ, Wiesenfeld
PL. L-Arginine inhibits in vitro nonenzymatic glycation and advanced
glycosylated end product formation of human serum albumin.
Amino Acids. 1996;11:69–81.
© 1998 American Heart Association, Inc.
Review
Review of Alterations in Endothelial Nitric Oxide Production in Diabetes
Protective Role of Arginine on Endothelial Dysfunction
Introduction
Nitric
oxide release from the endothelium plays an important
role in regulation of vascular tone,1 inhibition
of both platelet and leukocyte aggregation and
adhesion,1 2 and inhibition of cell
proliferation.3 These properties suggest that the
level of NO production by the endothelium may
play a pivotal role in the regulation of vascular disease.
Analysis using mass spectrometry has revealed that NO is
produced by NOS from the terminal guanidino nitrogen of the precursor
amino acid L-arginine.4 Thus,
utilization of L-arginine and conversion to NO may
establish a regulatory site in the development of
endothelial dysfunction.
Impaired Endothelium-Dependent Relaxation
Experimental Diabetes Mellitus
Decreases in endothelium-dependent relaxation are
a common feature in both conduit9 10 11 12 13 14 15 16 17 18 19 20 and
resistance21 22 23 24 25 26 27 28 29 30 arteries of chemically induced
experimental diabetic animals (including rats, mice, rabbits, hamsters,
and dogs). In two genetic models of IDDM, similar impaired relaxation
has been documented in aorta31 32 33 and mesenteric
arteries34 35 of diabetes-prone BB/Wor or BB/E
rats and in aorta36 and mesenteric
arteries37 of the diabetes-prone WBN/Kob rat.
The first evidence of endothelial dysfunction in
humans was reported in penile corpura cavernosa of IDDM and NIDDM
patients.42 Impaired
endothelium-dependent relaxation of conduit blood
vessels has been confirmed in both IDDM43 44 45 46 47 and
NIDDM43 48 49 50 51 52 53 patients evaluated in vivo or in
isolated arteries in vitro.45 51 A few studies in
IDDM54 55 56 or NIDDM
patients57 report no defect. One study of
resistance vessels derived from NIDDM patients and evaluated in vitro
showed enhanced reactivity to acetylcholine.58
Evaluation of the latter study is compromised because the control
patients selected exhibited arterial occlusive disease,
hypercholesterolemia, and other nondiabetic
diseases. Also, patients using various cardiovascular
medications were not excluded from the study.
Importance of Patient Screening and Other Complicating
Factors
One possible explanation of this variability relates to primary
nitrate tolerance, since responses to nitroglycerin but
not sodium nitroprusside were diminished in diabetic
patients.65 Alternatively, one of these studies
noted no difference in reactivity to nitroglycerin
after correction for differences in baseline
diameter.61 Furthermore, diabetic patients with
microalbuminuria exhibited impaired dilation to isosorbide
dinitrate, while in diabetic patients without
microalbuminuria, dilation was
unaltered.66 In this regard, dilation in response
to carbachol was normal in diabetic patients but was blunted by an NOS
inhibitor in both control and diabetic patients without
microalbuminuria but not in diabetic patients with
microalbuminuria.56 Thus, there may
be variable mechanisms of impaired vascular reactivity to
nitrovasodilators among different diabetic patient subpopulations.
Confounding Effects of Ambient Glucose Concentration
Ambient plasma glucose concentration could be a confounding factor
in vivo as well. Some studies in experimental animal models have noted
acute vasodilation (ie, seconds to minutes) in response to concurrent
elevation in glucose concentration.73 74 75 In
contrast, short-term exposure (ie, minutes to several hours) to
elevated glucose concentrations in vitro or topical application in situ
impairs basal NO tone76 and agonist-stimulated
endothelium-dependent
relaxation.77 78 79 80 81 Interestingly, 24-hour infusion
of glucose in normal subjects did not impair
relaxation.82 Because multiple agonists were used
in the latter study, the significance of masking by crossover effects
of individual drugs cannot be excluded in the interpretation of this
data. In contrast, evaluation during an acute bolus of glucose
administration (ie, during a glucose tolerance test) revealed decreased
endothelium-dependent
relaxation.83
Paradoxical Findings on Endothelial Function: Role
of Disease Duration
Few studies have examined the temporal nature of the onset of
endothelial dysfunction in experimental diabetes. Most
have shown a progressive worsening of dysfunction that appears to
plateau at some finite point in time. Dysfunction has been reported at
as early as 1 week of diabetes in rat intestinal
arterioles,30 after 2 weeks in hindquarters but
not in mesenteric or renal arteries,89 after 3
weeks in cremaster muscle arterioles,90 after 4
to 6 weeks in mesenteric arterioles,25 91 and
after 4 weeks in aorta.70 Thus, lack of
endothelial dysfunction of diabetic rat aorta at 2 to 3
weeks of disease92 could be explained by the
short period of time studied. It is important to note that the onset of
endothelial dysfunction may vary widely among
individual vascular beds and/or the severity of the diabetic model used
in any given study.
Role of Prostanoids in Endothelium-Dependent
Dilation in Diabetes
Impaired endothelium-dependent relaxation in
diabetes cannot always be assumed to be mediated by a reduction in NO
activity or synthesis, since some vasodilators also release
prostaglandins. Changes in prostaglandin
synthesis may alter NO production or reactivity to NO. Because
diabetes alters the reactivity to prostanoids and may either increase
or decrease prostacyclin production depending on the artery
chosen,105 this issue needs to be resolved,
especially at various stages of disease and in individual blood vessel
preparations.
NO-Dependent or -Independent Endothelial Dysfunction
Implicit in all of these studies is the assumption that
endothelium-dependent relaxation in both control and
diabetic blood vessels is exclusively mediated via NO. This assumption
is hazardous because endothelium-dependent relaxation
to certain agonists and in certain arteries appears to be mediated in
part by vasodilator prostanoids or by an EDHF.119
The entity of EDHF is not known with complete certainty, but at least
one EDHF is believed to be an epoxide of arachidonic
acid that is formed by a cytochrome P450–derived
monooxygenase.120
Evidence Supporting Altered NO Production From
Diabetic Endothelium
Functional Studies in the Presence of SOD
NO activity is known to be reduced by chemical interaction and
destruction by superoxide anion radicals. Several investigators have
noted improved relaxation after acute incubation with
SOD.14 25 26 33 77 117 132 This issue has been
discussed in detail in a previous review.7
Nevertheless, these studies are consistent with increased
destruction of NO and decreased bioactivity of NO in diabetes, but they
do not give adequate direct information regarding perturbations in NO
production.
Use of inhibitors of NOS or NO reactivity (eg,
hemoglobin or methylene blue) has given indirect information regarding
the contribution of NO to basal tone and agonist-induced relaxation in
control versus diseased blood vessels. Many studies that have used
removal of endothelium or NOS inhibitors or
hemoglobin, which increase the precontracted tone of arteries, reveal
decreased basal NO activity in both diabetic
conduit16 94 134 135 136 137 138 139 140 and
resistance24 25 35 132 140 141 142 143 144 145 arteries under
both in vitro and in vivo conditions.
Basal NO activity in rat aorta has also been assessed using either
a small-molecular-weight, iron-thiol-based NO
scavenger149 or a nitronyl nitroxide trapping
agent.148 These agents are different in that they
do not alter NOS activity but react with NO after its release. These
probes were effective in scavenging all basal NO based on similar
tension responses after removal of endothelium or by
using NOS inhibitors and confirm a smaller basal NO
activity in diabetic rat aorta. This NO scavenger–sensitive basal NO
activity was augmented by L-arginine in diabetic but not
control aorta.149
Information regarding potential deficits in NO synthesis have also
been derived from measurement of cGMP in vascular tissue. Although one
study showed no significant alteration in basal and
acetylcholine-stimulated cGMP in alloxan-diabetic
aorta,150 an earlier study in the same animal
model showed that diabetes decreased both basal and
acetylcholine-stimulated cGMP.19 The latter study
differed only in that duration of disease was longer and that a
preconstrictor agonist was used in the assays. Similar decreases in
acetylcholine-stimulated cGMP production have been observed in
rat and rabbit aorta and mesenteric
arteries,12 19 151 152 in canine coronary
arteries,107 and in isolated rat
glomeruli.153 154 In contrast, cGMP in response
to nitroprusside was diminished in isolated glomeruli from diabetic
rats.153 In the presence of the phosphodiesterase
inhibitor IBMX and after stimulation with nitroprusside,
cGMP production was not altered by diabetes in rat
aorta152 or
glomeruli.154
To our knowledge, there has been no direct measurement of NO from
diabetic arteries using NO electrodes or an NO analyzer.
According to indirect measurements of the NO-based by-products
nitrate and nitrite, levels of either nitrite or nitrate+nitrite
in urine of diabetic rats were
increased.26 142 155 156 157 158 159 160 161
Streptozotocin, the agent frequently used to produce experimental
diabetes, is also a known NO donor compound.162
This property could potentially contribute to enhanced urinary
nitrate/nitrite levels at early stages of diabetes. This limitation is
likely not a problem for samples taken several weeks after the
administration of streptozotocin. Furthermore, the increased urinary
nitrate+nitrite might simply be secondary to hyperfiltration. Although
some studies have controlled for nitrate/nitrite derived from food
during diabetes-induced hyperphagia, most have not controlled for
variation in nitrate consumption derived from drinking water due to
diabetes-induced increases in water consumption or for NO released
simply because of the mechanical stimuli of increased renal blood flow
and filtration due to excess volume disposal as a consequence of
diabetes. Thus, the relationship between urinary nitrate/nitrite
concentration and vascular endothelium
production of NO must be understood in the context of these
significant limitations.
There is little information available concerning measurement of
endothelial cell NOS protein content or mRNA in
diabetes mellitus. Diaphorase staining and
immunohistochemical staining suggest reduced NOS activity in
sympathetic autonomic ganglia165 and macula
densa166 of experimental diabetic rats. Another
study revealed a decrease in mRNA and content of neuronal NOS (nNOS) in
diabetic penile tissue.167 Interestingly, one
study in diabetic rat heart homogenates noted increased NOS
activity (believed to be largely constitutive NOS [cNOS]) determined
by arginine to citrulline conversion along with increased cNOS mRNA and
protein.26 There was no detectable inducible NOS
(iNOS), although induction of iNOS was previously reported in placenta
of gestational diabetic patients.168 In rat renal
tissue at 1 week of diabetes, mRNA and protein for cNOS, iNOS, and nNOS
were all increased in cortex but unchanged in
medulla.169
Arginine Deficiency and/or Substrate Utilization by NOS
Plasma arginine concentration is decreased in diabetic
rats26 138 159 173 174 and in some human diabetic
patients.175 176 In contrast, some reports
involving a small number of patients have reported normal arginine
levels.177 178 In streptozotocin-induced
diabetes, decreases in plasma arginine and endothelial
dysfunction are corrected by subsequent transplantation of either whole
pancreas179 or pancreatic
islets.174 
100
µmol/L). Furthermore, the maximum capacity for arginine transport is
much lower for smooth muscle compared with endothelial
cells. These effects might limit the amount of arginine transported by
smooth muscle cells and subsequently delivered to
endothelial cells to improve NO synthesis in topical
application protocols.
Effects of Arginine on NO in Human Diabetes
The possibility that NO deficits occur in clinical diabetes arises
from a report showing that arginine increases plasma nitrate/nitrite
levels in diabetic patients.200 Unfortunately,
the effects of arginine in control patients was not evaluated. In one
study, arginine increased nitrates and exhaled NO by nearly equivalent
degrees in control and IDDM patients.163 The
effects of arginine administration in vivo must be interpreted with
caution because arginine also increases insulin
secretion201 and the arginine stimulus might be
altered by disease.202 Insulin is reported to
cause dilation via stimulation of NO
production,203 204 205 although one recent
report shows that insulin can produce dilation in the presence of an
NOS inhibitor or can be blocked by adenosine
receptor antagonists or
KATP-sensitive channel
blockers.206
Are Effects of Arginine NO/cGMP–Dependent?
It has been widely assumed that the
L-arginine–induced improvement in
endothelium-dependent relaxation in various other
models of vascular disease reflects enhanced NO/cGMP
production. The fallacy of this assumption remains to be
rigorously tested in diabetic models, since NO can elicit
cGMP-independent effects in some tissue. For example,
L-arginine augmented endothelium-dependent
relaxation in hypertensive arteries via an NO-independent pathway
involving cyclooxygenase-derived reactive
oxygen.210 Furthermore, there are studies that
show that arginine analogues which inhibit NOS also alter prostanoid
synthesis211 and
KATP-mediated
relaxation.212 Thus, it is possible that arginine
supplementation might improve relaxation in diabetic arteries via
alternative NO-independent pathways.
Effects of Arginine on Endothelial Dysfunction
Produced by Elevated Glucose Concentration In Vitro or Hyperglycemia
In Vivo
One study noted that flow reduction in normal isolated guinea pig
hearts resulted in vasoconstriction that was reversed by
L-arginine.213 In contrast, the acute
vasodilation produced by flow reduction in the presence of 44
mmol/L D-glucose was augmented by L-arginine.
This suggests that arginine may play an important role in
autoregulation under high glucose conditions.
Potential Actions of Chronic Arginine Treatment on Endothelial
Function
In addition to potential action on insulin release, chronic
arginine administration may provide multiple benefits to ameliorate
diabetes-induced endothelial dysfunction for other
reasons. Arginine administration reduces lipid peroxide levels in
diabetic patients.215 Arginine inhibits lipid
peroxidation in vitro and has been reported to be a direct scavenger of
superoxide anions.216 Other studies do not
support a direct scavenger action for
arginine.217 Alternatively,
L-arginine might enhance relaxation by increasing NO
release, which in turn scavenges enhanced rates of superoxide anion
production that are elevated in diabetic
arteries.33 114 135
Selected Abbreviations and Acronyms
EDHF
=
endothelium-derived hyperpolarizing factor
IDDM
=
insulin-dependent diabetes mellitus
NIDDM
=
non–insulin-dependent diabetes mellitus
NO(S)
=
nitric oxide (synthase)
ODQ
=
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one
SOD
=
superoxide dismutase
TEA
=
tetraethylammonium
Acknowledgments
This work was supported by National Institutes of Health
grant HL47072.
References
1.
Moncada S, Palmer RMJ, Higgs EA. Nitric oxide:
physiology, pathophysiology and pharmacology. Pharmacol
Rev. 1991;43:109–142.[Medline]
[Order article via Infotrieve]
Top
Introduction
Impaired Endothelium-Dependent...This article has been cited by other articles:
 |
|
 |
|
  T. Kobayashi, K. Taguchi, S. Nemoto, T. Nogami, T. Matsumoto, and K. Kamata Activation of the PDK-1/Akt/eNOS pathway involved in aortic endothelial function differs between hyperinsulinemic and insulin-deficient diabetic rats Am J Physiol Heart Circ Physiol, November 1, 2009; 297(5): H1767 - H1775. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Matsumoto, N. Nakayama, K. Ishida, T. Kobayashi, and K. Kamata Eicosapentaenoic Acid Improves Imbalance between Vasodilator and Vasoconstrictor Actions of Endothelium-Derived Factors in Mesenteric Arteries from Rats at Chronic Stage of Type 2 Diabetes J. Pharmacol. Exp. Ther., April 1, 2009; 329(1): 324 - 334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Matsumoto, E. Noguchi, K. Ishida, T. Kobayashi, N. Yamada, and K. Kamata Metformin normalizes endothelial function by suppressing vasoconstrictor prostanoids in mesenteric arteries from OLETF rats, a model of type 2 diabetes Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1165 - H1176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. W. Brands and H. Labazi Role of Glomerular Filtration Rate in Controlling Blood Pressure Early in Diabetes Hypertension, August 1, 2008; 52(2): 188 - 194. [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Harris, M. M. Elgebaly, W. Li, K. Sachidanandam, and A. Ergul Effect of chronic endothelin receptor antagonism on cerebrovascular function in type 2 diabetes Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2008; 294(4): R1213 - R1219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ren, J. Duan, D. P. Thomas, X. Yang, N. Sreejayan, J. R. Sowers, A. Leri, J. Kajstura, F. Gao, and P. Anversa IGF-I alleviates diabetes-induced RhoA activation, eNOS uncoupling, and myocardial dysfunction Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2008; 294(3): R793 - R802. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Wu, J. K. Collins, P. Perkins-Veazie, M. Siddiq, K. D. Dolan, K. A. Kelly, C. L. Heaps, and C. J. Meininger Dietary Supplementation with Watermelon Pomace Juice Enhances Arginine Availability and Ameliorates the Metabolic Syndrome in Zucker Diabetic Fatty Rats J. Nutr., December 1, 2007; 137(12): 2680 - 2685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Matsumoto, M. Kakami, E. Noguchi, T. Kobayashi, and K. Kamata Imbalance between endothelium-derived relaxing and contracting factors in mesenteric arteries from aged OLETF rats, a model of Type 2 diabetes Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1480 - H1490. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Simionescu Implications of Early Structural-Functional Changes in the Endothelium for Vascular Disease Arterioscler Thromb Vasc Biol, February 1, 2007; 27(2): 266 - 274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Elrod, M. R. Duranski, W. Langston, J. J.M. Greer, L. Tao, T. R. Dugas, C. G. Kevil, H. C. Champion, and D. J. Lefer eNOS Gene Therapy Exacerbates Hepatic Ischemia-Reperfusion Injury in Diabetes: A Role for eNOS Uncoupling Circ. Res., July 7, 2006; 99(1): 78 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Komers, W. E. Schutzer, J. F. Reed, J. N. Lindsley, T. T. Oyama, D. C. Buck, S. L. Mader, and S. Anderson Altered Endothelial Nitric Oxide Synthase Targeting and Conformation and Caveolin-1 Expression in the Diabetic Kidney Diabetes, June 1, 2006; 55(6): 1651 - 1659. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Ito, Y. P. R. Jarajapu, D. L. Guberski, M. B. Grant, and H. J. Knot Myogenic Tone and Reactivity of Rat Ophthalmic Artery in Acute Exposure to High Glucose and in a Type II Diabetic Model Invest. Ophthalmol. Vis. Sci., February 1, 2006; 47(2): 683 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Bubolz, H. Li, Q. Wu, and Y. Liu Enhanced oxidative stress impairs cAMP-mediated dilation by reducing Kv channel function in small coronary arteries of diabetic rats Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H1873 - H1880. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Matsumoto, T. Kobayashi, K. Wakabayashi, and K. Kamata Cilostazol improves endothelium-derived hyperpolarizing factor-type relaxation in mesenteric arteries from diabetic rats Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H1933 - H1940. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Matsumoto, K. Wakabayashi, T. Kobayashi, and K. Kamata Functional changes in adenylyl cyclases and associated decreases in relaxation responses in mesenteric arteries from diabetic rats Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H2234 - H2243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Weekers, B. Bouhanick, S. Hadjadj, Y. Gallois, R. Roussel, F. Pean, A. Ankotche, G. Chatellier, F. Alhenc-Gelas, P. J. Lefebvre, et al. Modulation of the Renal Response to ACE Inhibition by ACE Insertion/Deletion Polymorphism During Hyperglycemia in Normotensive, Normoalbuminuric Type 1 Diabetic Patients Diabetes, October 1, 2005; 54(10): 2961 - 2967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. J. Fu, T. E. Haynes, R. Kohli, J. Hu, W. Shi, T. E. Spencer, R. J. Carroll, C. J. Meininger, and G. Wu Dietary L-Arginine Supplementation Reduces Fat Mass in Zucker Diabetic Fatty Rats J. Nutr., April 1, 2005; 135(4): 714 - 721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kobayashi, K. Taguchi, T. Yasuhiro, T. Matsumoto, and K. Kamata Impairment of PI3-K/Akt Pathway Underlies Attenuated Endothelial Function in Aorta of Type 2 Diabetic Mouse Model Hypertension, December 1, 2004; 44(6): 956 - 962. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Matsumoto, K. Wakabayashi, T. Kobayashi, and K. Kamata Diabetes-related changes in cAMP-dependent protein kinase activity and decrease in relaxation response in rat mesenteric artery Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1064 - H1071. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Setty, W. Sun, R. Martinez, H. F. Downey, and J. D. Tune {alpha}-Adrenoceptor-mediated coronary vasoconstriction is augmented during exercise in experimental diabetes mellitus J Appl Physiol, July 1, 2004; 97(1): 431 - 438. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kobayashi, T. Matsumoto, K. Ooishi, and K. Kamata Differential expression of {alpha}2D-adrenoceptor and eNOS in aortas from early and later stages of diabetes in Goto-Kakizaki rats Am J Physiol Heart Circ Physiol, July 1, 2004; 287(1): H135 - H148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Sigaudo-Roussel, C. Demiot, B. Fromy, A. Koitka, G. Leftheriotis, P. Abraham, and J. L. Saumet Early Endothelial Dysfunction Severely Impairs Skin Blood Flow Response to Local Pressure Application in Streptozotocin-Induced Diabetic Mice Diabetes, June 1, 2004; 53(6): 1564 - 1569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Komers, R. Simkova, L. Kazdova, J. Ruzickova, and T. Pelikanova Effects of ACE inhibition and AT1-receptor blockade on haemodynamic responses to L-arginine in Type 1 diabetes Journal of Renin-Angiotensin-Aldosterone System, March 1, 2004; 5(1): 33 - 38. [Abstract] [PDF]
|
|
|
|
|
|
A. Koitka, P. Abraham, B. Bouhanick, D. Sigaudo-Roussel, C. Demiot, and J. L. Saumet Impaired Pressure-Induced Vasodilation at the Foot in Young Adults With Type 1 Diabetes Diabetes, March 1, 2004; 53(3): 721 - 725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kohli, C. J. Meininger, T. E. Haynes, W. Yan, J. T. Self, and G. Wu Dietary L-Arginine Supplementation Enhances Endothelial Nitric Oxide Synthesis in Streptozotocin-Induced Diabetic Rats J. Nutr., March 1, 2004; 134(3): 600 - 608. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Gunnett, D. D. Heistad, and F. M. Faraci Gene-Targeted Mice Reveal a Critical Role for Inducible Nitric Oxide Synthase in Vascular Dysfunction During Diabetes Stroke, December 1, 2003; 34(12): 2970 - 2974. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Bagi, A. Koller, and G. Kaley Superoxide-NO interaction decreases flow- and agonist-induced dilations of coronary arterioles in Type 2 diabetes mellitus Am J Physiol Heart Circ Physiol, October 1, 2003; 285(4): H1404 - H1410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Morris, S. M. Morris Jr., W. Hagar, J. van Warmerdam, S. Claster, D. Kepka-Lenhart, L. Machado, F. A. Kuypers, and E. P. Vichinsky Arginine Therapy: A New Treatment for Pulmonary Hypertension in Sickle Cell Disease? Am. J. Respir. Crit. Care Med., July 1, 2003; 168(1): 63 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Matsumoto, T. Kobayashi, and K. Kamata Alterations in EDHF-type relaxation and phosphodiesterase activity in mesenteric arteries from diabetic rats Am J Physiol Heart Circ Physiol, June 5, 2003; 285(1): H283 - H291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Komers and S. Anderson Paradoxes of nitric oxide in the diabetic kidney Am J Physiol Renal Physiol, June 1, 2003; 284(6): F1121 - F1137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Flores, S. Rojas, C. Aguayo, J. Parodi, G. Mann, J. D. Pearson, P. Casanello, and L. Sobrevia Rapid Stimulation of L-Arginine Transport by D-Glucose Involves p42/44mapk and Nitric Oxide in Human Umbilical Vein Endothelium Circ. Res., January 10, 2003; 92(1): 64 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Fernandez-Real, G. Penarroja, C. Richart, A. Castro, J. Vendrell, M. Broch, A. Lopez-Bermejo, and W. Ricart G Protein {beta}3 Gene Variant, Vascular Function, and Insulin Sensitivity in Type 2 Diabetes Hypertension, January 1, 2003; 41(1): 124 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Mullan, I. S. Young, H. Fee, and D. R. McCance Ascorbic Acid Reduces Blood Pressure and Arterial Stiffness in Type 2 Diabetes Hypertension, December 1, 2002; 40(6): 804 - 809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kobayashi and K. Kamata Short-term insulin treatment and aortic expressions of IGF-1 receptor and VEGF mRNA in diabetic rats Am J Physiol Heart Circ Physiol, November 1, 2002; 283(5): H1761 - H1768. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Yorek, L. J. Coppey, J. S. Gellett, E. P. Davidson, X. Bing, D. D. Lund, and J. S. Dillon Effect of treatment of diabetic rats with dehydroepiandrosterone on vascular and neural function Am J Physiol Endocrinol Metab, November 1, 2002; 283(5): E1067 - E1075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. T. Huynh and J. A. Tayek Oral Arginine Reduces Systemic Blood Pressure in Type 2 Diabetes: Its Potential Role in Nitric Oxide Generation J. Am. Coll. Nutr., October 1, 2002; 21(5): 422 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Chandra, E. B. Jackson, K. V. Ramana, R. Kelley, S. K. Srivastava, and A. Bhatnagar Nitric Oxide Prevents Aldose Reductase Activation and Sorbitol Accumulation During Diabetes Diabetes, October 1, 2002; 51(10): 3095 - 3101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Thomsen, I. Rubin, and M. Lauritzen NO- and non-NO-, non-prostanoid-dependent vasodilatation in rat sciatic nerve during maturation and developing experimental diabetic neuropathy J. Physiol., September 15, 2002; 543(3): 977 - 993. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Tousoulis, C. Antoniades, C. Tentolouris, G. Goumas, C. Stefanadis, and P. Toutouzas L-Arginine in cardiovascular disease: dream or reality? Vascular Medicine, August 1, 2002; 7(3): 203 - 211. [Abstract] [PDF]
|
|
|
|
|
|
C. A. Gunnett, D. D. Heistad, and F. M. Faraci Interleukin-10 Protects Nitric Oxide-Dependent Relaxation During Diabetes: Role of Superoxide Diabetes, June 1, 2002; 51(6): 1931 - 1937. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Fromy, P. Abraham, C. Bouvet, B. Bouhanick, P. Fressinaud, and J. L. Saumet Early Decrease of Skin Blood Flow in Response to Locally Applied Pressure in Diabetic Subjects Diabetes, April 1, 2002; 51(4): 1214 - 1217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Parodi, C. Flores, C. Aguayo, M. I. Rudolph, P. Casanello, and L. Sobrevia Inhibition of Nitrobenzylthioinosine-Sensitive Adenosine Transport by Elevated D-Glucose Involves Activation of P2Y2 Purinoceptors in Human Umbilical Vein Endothelial Cells Circ. Res., March 22, 2002; 90(5): 570 - 577. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Misurski, R. L. Hopfner, and V. Gopalakrishnan Attenuated Agonist Evoked Vasoconstrictor Responses in the Perfused Mesenteric Vascular Bed of Streptozotocin Diabetic Rats Experimental Biology and Medicine, November 1, 2001; 226(10): 940 - 946. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Rask-Madsen, N. Ihlemann, T. Krarup, E. Christiansen, L. Kober, C. Nervil Kistorp, and C. Torp-Pedersen Insulin Therapy Improves Insulin-Stimulated Endothelial Function in Patients With Type 2 Diabetes and Ischemic Heart Disease Diabetes, November 1, 2001; 50(11): 2611 - 2618. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. T. Davidge Prostaglandin H Synthase and Vascular Function Circ. Res., October 12, 2001; 89(8): 650 - 660. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. I. Zharikov, A. A. Sigova, S. Chen, M. R. Bubb, and E. R. Block Cytoskeletal regulation of the L-arginine/NO pathway in pulmonary artery endothelial cells Am J Physiol Lung Cell Mol Physiol, March 1, 2001; 280(3): L465 - L473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Kimura, M. Oike, T. Koyama, and Y. Ito Impairment of endothelial nitric oxide production by acute glucose overload Am J Physiol Endocrinol Metab, January 1, 2001; 280(1): E171 - E178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. SCALIA, K. M. COYLE, B. J. LEVINE, G. BOOTH, and A. M. LEFER C-peptide inhibits leukocyte-endothelium interaction in the microcirculation during acute endothelial dysfunction FASEB J, November 1, 2000; 14(14): 2357 - 2364. [Abstract] [Full Text]
|
|
|
|
|
|
G. Wu and C. J. Meininger Arginine Nutrition and Cardiovascular Function J. Nutr., November 1, 2000; 130(11): 2626 - 2629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Fitzgerald and M. W. Brands Nitric oxide may be required to prevent hypertension at the onset of diabetes Am J Physiol Endocrinol Metab, October 1, 2000; 279(4): E762 - E768. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Young, Y. Ikeda, R. Scalia, and A. M. Lefer C-peptide exerts cardioprotective effects in myocardial ischemia-reperfusion Am J Physiol Heart Circ Physiol, October 1, 2000; 279(4): H1453 - H1459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Komers, J. N. Lindsley, T. T. Oyama, K. M. Allison, and S. Anderson Role of neuronal nitric oxide synthase (NOS1) in the pathogenesis of renal hemodynamic changes in diabetes Am J Physiol Renal Physiol, September 1, 2000; 279(3): F573 - F583. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. PIATTI, L. D. MONTI, I. ZAVARONI, G. VALSECCHI, C. VAN PHAN, S. COSTA, M. CONTI, E. P. SANDOLI, B. SOLERTE, G. POZZA, et al. Alterations in Nitric Oxide/Cyclic-GMP Pathway in Nondiabetic Siblings of Patients with Type 2 Diabetes J. Clin. Endocrinol. Metab., July 1, 2000; 85(7): 2416 - 2420. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. G. Seo, T. Nishinaka, and C. Yabe-Nishimura Nitric Oxide Up-Regulates Aldose Reductase Expression in Rat Vascular Smooth Muscle Cells: A Potential Role for Aldose Reductase in Vascular Remodeling Mol. Pharmacol., April 1, 2000; 57(4): 709 - 717. [Abstract] [Full Text]
|
|
|
|
|
|
R. Komers, T. T. Oyama, J. G. Chapman, K. M. Allison, and S. Anderson Effects of Systemic Inhibition of Neuronal Nitric Oxide Synthase in Diabetic Rats Hypertension, February 1, 2000; 35(2): 655 - 661. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. R. Claxton, M. W. Brands, S. M. Fitzgerald, and J. A. Cameron Inhibition of Nitric Oxide Synthesis Potentiates Hypertension During Chronic Glucose Infusion in Rats Hypertension, January 1, 2000; 35(1): 451 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Lim, A. E. Caballero, S. Arora, P. Smakowski, E. M. Bashoff, F. M. Brown, F. W. Logerfo, E. S. Horton, and A. Veves The Effect of Hormonal Replacement Therapy on the Vascular Reactivity and Endothelial Function of Healthy Individuals and Individuals with Type 2 Diabetes J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 4159 - 4164. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Joyeux, P. Faure, D. Godin-Ribuot, S. Halimi, A. Patel, D. M Yellon, P. Demenge, and C. Ribuot Heat stress fails to protect myocardium of streptozotocin-induced diabetic rats against infarction Cardiovasc Res, September 1, 1999; 43(4): 939 - 946. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Kojda and D. Harrison Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure Cardiovasc Res, August 15, 1999; 43(3): 652 - 671. [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. MILLER Impact of Hyperglycemia on the Renin Angiotensin System in Early Human Type 1 Diabetes Mellitus J. Am. Soc. Nephrol., August 1, 1999; 10(8): 1778 - 1785. [Abstract] [Full Text]
|
|
|
|
|
|
S. A. Gupte, T. Rupawalla, K. M. Mohazzab-H., and M. S. Wolin Regulation of NO-elicited pulmonary artery relaxation and guanylate cyclase activation by NADH oxidase and SOD Am J Physiol Heart Circ Physiol, May 1, 1999; 276(5): H1535 - H1542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Pflueger, H. Osswald, and F. G. Knox Adenosine-induced renal vasoconstriction in diabetes mellitus rats: role of nitric oxide Am J Physiol Renal Physiol, March 1, 1999; 276(3): F340 - F346. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-M. Fernandez-Real, B. Lainez, J. Vendrell, M. Rigla, A. Castro, G. Penarroja, M. Broch, A. Perez, C. Richart, P. Engel, et al. Shedding of TNF-alpha receptors, blood pressure, and insulin sensitivity in type 2 diabetes mellitus Am J Physiol Endocrinol Metab, April 1, 2002; 282(4): E952 - E959. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Fitzgerald and M. W. Brands Hypertension in L-NAME-treated diabetic rats depends on an intact sympathetic nervous system Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2002; 282(4): R1070 - R1076. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Parodi, C. Flores, C. Aguayo, M. I. Rudolph, P. Casanello, and L. Sobrevia Inhibition of Nitrobenzylthioinosine-Sensitive Adenosine Transport by Elevated D-Glucose Involves Activation of P2Y2 Purinoceptors in Human Umbilical Vein Endothelial Cells Circ. Res., March 22, 2002; 90(5): 570 - 577. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Guzik, S. Mussa, D. Gastaldi, J. Sadowski, C. Ratnatunga, R. Pillai, and K. M. Channon Mechanisms of Increased Vascular Superoxide Production in Human Diabetes Mellitus: Role of NAD(P)H Oxidase and Endothelial Nitric Oxide Synthase Circulation, April 9, 2002; 105(14): 1656 - 1662. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||